Compositions and methods for increasing muscle mass and oxidative metabolism

Abstract

To provide compounds to increase muscle mass, muscle oxidative capacity, and muscle function and to treat muscular dystrophy, in particular limb girdle muscular dystrophy type 2A / R1 / D1, compositions including the compounds, and treatment methods.SOLUTION: The present invention provides a compound having the chemical structure of formula (I), and a composition comprising the compound or a pharmaceutically acceptable salt or solvate thereof.SELECTED DRAWING: None

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Application No. 62 / 833,037, filed April 12, 2019, which is incorporated by reference in its entirety.

[0002] FIELD OF THEINVENTION The present invention relates generally to the field of medicine, and more particularly to compositions and methods for improving muscle mass and function and for treating muscular dystrophy, particularly limb-girdle muscular dystrophy type 2A. [Background technology]

[0003] Muscular dystrophies are a group of more than 30 genetic disorders. Muscular dystrophies cause muscle weakness and loss of muscle mass and can be present at any time in life, including childhood. Muscular dystrophies worsen with the patient's muscle weakness and can eventually cause a disabling condition. Limb-girdle muscular dystrophies are usually manifested in the proximal limb and girdle muscles, causing weakness and atrophy of these muscles. Limb-girdle muscular dystrophy type 2A (LGMD2A / R1) is the most common form of limb-girdle muscular dystrophy, accounting for approximately 30 percent of cases. This form of limb-girdle muscular dystrophy is an autosomal recessive limb-girdle muscular dystrophy characterized by the symmetric progression of muscle weakness of the proximal limb and girdle muscles without cardiac involvement or intellectual disability. There is also an autosomal dominant form, designated LGMD D1, that manifests with a similar clinical phenotype.

[0004] Currently, there is no cure for any form of muscular dystrophy. Current first-line treatment methods include physical therapy, orthopedic devices, surgery, and medication. Treatment is primarily aimed at relieving symptoms and preventing complications. For example, current LGMD2A treatments are primarily aimed at maintaining mobility and preventing complications. Therefore, there is a need for compositions and methods for treating muscular dystrophy. Summary of the Invention

[0005] It has been identified that compounds having the chemical structure of Formula I and / or Formula VII, or pharma- ceutically acceptable salts or solvates thereof, can improve muscle mass, muscle function, and / or oxidative metabolism. Such chemicals can be effective in treating muscular dystrophies, such as limb-girdle muscular dystrophy type 2A / R1 / D1.

[0006] Certain embodiments are represented by formula I The target compound is an AMBMP analog having the chemical structure of TIFF2025000907000001.tif59128. In the formula, R 1 and R 2 are independently selected from H, alkyl, substituted alkyl, aryl, or R 1 and R 2 together form a 4- to 6-membered heterocyclic ring; R 3 and R 4 are independently selected from H, alkyl, substituted alkyl, aryl, or R 3 and R 4 is a bond forming a 5-membered heterocyclic ring, or R 3 and R 4 together form a six-membered heterocyclic ring; R 5 and R 6 are independently selected from H, alkyl, substituted alkyl, aryl, or R 5 and R 6 is a bond forming a 5-membered heterocyclic ring, or R 5 and R 6 taken together form a 6-membered heterocycle; X is selected from a group having the chemical structure of Formula II, Formula III, Formula IV, or Formula V: For formula II, Z is H, alkyl, substituted alkyl, aryl, OR 7 , or N.R. 8 R 9 Selected from R 7is selected from H, alkyl, haloalkyl, substituted alkyl, or aryl; R 8 and R 9 are independently selected from H, alkyl, substituted alkyl, aryl, or R 8 and R 9 together form a 4- to 6-membered heterocyclic ring; J 1 is H, alkyl, or OR 10 Selected from; R 10 is H, alkyl, haloalkyl, substituted alkyl, aryl, or ((CH2) n O) p CH2CH2R 11 (n is 1, 2, or 3; p is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10); R 11 is OH, NH2, or alkoxy; J 2 is H, alkyl, or OR 12 Selected from; R 12 is H, alkyl, haloalkyl, substituted alkyl, aryl, or ((CH2) n O) p CH2CH2R 13 (n is 1, 2, or 3; p is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10); R 13 is OH, NH2, or alkoxy; For formula III, M is selected from O, NH, or CH2; TIFF2025000907000004.tif90128 About Formula V, R 14 is H or alkoxy, R 15 is H or alkoxy; Formula I is not Formula VI below. TIFF2025000907000005.tif54128

[0007] In some embodiments, X is of Formula II. In some particular embodiments, X is of Formula II and J1 is OCH3.

[0008] In some embodiments, R 1 is H and R 2 is H and R 3 is H and R 4 is H and R 5 and R 6 is a bond forming a 5-membered heterocycle and X is of formula II. Figure 1 shows various examples of such compounds.

[0009] In some embodiments, R 1 is H and R 2 is H and R 3 is H and R 4 is H and R 5 and R 6 is a bond forming a 5-membered heterocycle, X is of formula II, Z is H, and J 2 is H and J 1 OR 10 Various examples of such compounds are shown in Figures 1A-1L. In some particular embodiments, R 10 is CF3, and a non-limiting chemical structure of this compound is shown in Figure 1A. In some particular embodiments, R 10 is CH(CH), and a non-limiting chemical structure of this compound is shown in FIG. 1B. In some particular embodiments, R 10 is H, and a non-limiting chemical structure of this compound is shown in FIG. 1C. In some particular embodiments, R 10 is CH2CH3, and a non-limiting chemical structure of this compound is shown in Figure ID. In some particular embodiments, R 10 is CH2CH2CH3, and a non-limiting chemical structure of this compound is shown in Figure 1E. In some particular embodiments, R 10 is C(CH3)3, and a non-limiting chemical structure of this compound is shown in Figure 1F. In some particular embodiments, R 10 is CH2CH2OCH3, and a non-limiting chemical structure of this compound is shown in Figure 1G. In some particular embodiments, R 10is CH2CH2OCH2CH2OCH2CH2OCH3, and a non-limiting chemical structure of this compound is shown in Figure 1H. In some particular embodiments, R 10 is CH2CH2OCH2CH2NH2, and a non-limiting chemical structure of this compound is shown in Figure 1I. In some particular embodiments, R 10 is CHNH, and a non-limiting chemical structure of this compound is shown in FIG. 1J. In some particular embodiments, R 10 is CH2CH2NH2, and a non-limiting chemical structure of this compound is shown in Figure 1K. In some particular embodiments, R 10 is CH2CONH2, a non-limiting chemical structure of this compound is shown in Figure 1 L. In some embodiments, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more of the compounds discussed in this paragraph (or any range derivable therein) may be excluded.

[0010] In some embodiments, R 1 is H and R 2 is H and R 3 is H and R 4 is H and R 5 and R 6 is a bond forming a 5-membered heterocycle, X is of formula II, J 1 is OCH3, and J 2 is H, Z is alkyl, substituted alkyl, aryl, OR 7 , or N.R. 8 R 9 Selected from R 7 is selected from H, alkyl, haloalkyl, substituted alkyl, or aryl; R 8 and R 9 are independently selected from H, alkyl, substituted alkyl, aryl, or R 8 and R 9 taken together form a 4-6 membered heterocycle. Various examples of such compounds are shown in Figures 1M-1P. In some particular embodiments, Z is NR 8 R 9and R 8 and R 9 are taken together to form a four-membered heterocycle, and Figure 1M shows a non-limiting chemical structure of this compound. In some particular aspects, Z is NHCH3, and Figure 1N shows a non-limiting chemical structure of this compound. In some particular aspects, Z is NH2, and Figure 1O shows a non-limiting chemical structure of this compound. In some particular aspects, Z is CH3, and Figure 1P shows a non-limiting chemical structure of this compound. In some embodiments, one or more of the compounds discussed in this paragraph may be excluded.

[0011] In some embodiments, R 1 is H and R 2 is H and R 3 is H and R 4 is H and R 5 and R 6 is a bond forming a 5-membered heterocycle, X is of formula II, J 1 is H and J 2 is H, Z is H, alkyl, substituted alkyl, aryl, OR 7 , or N.R. 8 R 9 Selected from R 7 is selected from H, alkyl, haloalkyl, substituted alkyl, or aryl; R and R are independently selected from H, alkyl, substituted alkyl, aryl, or R 8 and R 9 are taken together to form a 4-6 membered heterocycle. Various examples of such compounds are shown in Figures 1Q-1T, 1V, 1X-1Z, and 1AA. In some specific embodiments, Z is OCF3, and a non-limiting chemical structure of this compound is shown in Figure 1Q. In some specific embodiments, Z is OCH3, and a non-limiting chemical structure of this compound is shown in Figure 1R. In some specific embodiments, Z is OCH2CH3, and a non-limiting chemical structure of this compound is shown in Figure 1S. In some specific embodiments, Z is NR 8 R 9 and R 8and R 9 are taken together to form a four-membered heterocycle, and Figure 1T shows a non-limiting chemical structure of the compound. In some embodiments, one or more of those discussed in this paragraph may be excluded. In some particular aspects, Z is OC(CH3)3, and Figure 1V shows a non-limiting chemical structure of the compound. In some particular aspects, Z is OCH2CONH2, and Figure 1X shows a non-limiting chemical structure of the compound. In some particular aspects, Z is OCH2CH2NH2, and Figure 1Y shows a non-limiting chemical structure of the compound. In some particular aspects, Z is OCH2CH2NHCH2CH3, and Figure 1Z shows a non-limiting chemical structure of the compound. In some particular aspects, Z is OCH2NHCH2CH(CH3)2, and Figure 1AA shows a non-limiting chemical structure of the compound.

[0012] In some embodiments, R 1 is H and R 2 is H and R 3 is H and R 4 is H and R 5 and R 6 is a bond forming a 5-membered heterocycle, X is of formula II, J 1 is OCH3, and J 2 is OCH3 and Z is H, and a non-limiting chemical structure of this compound is shown in Figure 1U. 1 is H and R 2 is H and R 3 is H and R 4 is H and R 5 and R 6 is a bond forming a 5-membered heterocycle, X is of formula II, J 1 is OCH3, J 2 is OH and Z is H, and a non-limiting chemical structure of this compound is shown in Figure 1W. 1 is H and R 2 is H and R 3 is H and R 4is H and R 5 and R 6 is a bond forming a 5-membered heterocycle, X is of formula II, J 1 is OCF3, J 2 is OCH3, Z is H, and a non-limiting chemical structure of this compound is shown in Figure 1BB.

[0013] In some embodiments, R 1 is H and R 2 is H and R 3 is H and R 4 is H and R 5 and R 6 is a bond forming a 5-membered heterocycle, X is formula III, and M is O, NH, or CH2. Various examples of such compounds are shown in Figure 2. In some particular aspects, M is O, and a non-limiting chemical structure of the compound is shown in Figure 2A. In some particular aspects, M is NH, and a non-limiting chemical structure of the compound is shown in Figure 2B. In some particular aspects, M is CH2, and a non-limiting chemical structure of the compound is shown in Figure 2C. In some embodiments, one or more of those discussed in this paragraph may be excluded.

[0014] In some embodiments, R 1 is H and R 2 is H and R 3 is H and R 4 is H and R 5 and R 6 is a bond forming a 5-membered heterocycle, and X is of formula IV, and a non-limiting chemical structure of this compound is shown in Figure 3. In some embodiments, one or more of the compounds discussed in this paragraph may be excluded.

[0015] In some embodiments, R 3 is H and R 4 is H and R 5 and R 6 is a bond forming a 5-membered heterocycle, X is of formula II, J1 is OCH3, Z is H, J 2 is H and R 1 and R 2 are independently selected from H, alkyl, substituted alkyl, aryl, or R 1 and R 2 taken together form a 4-6 membered heterocycle. Various examples of such compounds are shown in Figure 4. In some particular embodiments, R 1 is H and R 2 is CH3, and a non-limiting chemical structure of this compound is shown in Figure 4A. In some particular embodiments, R 1 is CH3, R 2 is CH3, and a non-limiting chemical structure of this compound is shown in Figure 4B. In some particular embodiments, R 1 and R 2 taken together form a four-membered heterocycle, a non-limiting chemical structure of which is shown in Figure 4C. In some particular embodiments, R 1 and R 2 taken together form a 5-membered heterocycle, a non-limiting chemical structure of which is shown in Figure 4D. In some particular embodiments, R 1 is H and R 2 is p-CHCHCN, and a non-limiting chemical structure of this compound is shown in FIG. 4E. In some particular embodiments, R 1 is H and R 2 is p-CHCHCCH, and a non-limiting chemical structure of this compound is shown in FIG. 4F. In some particular embodiments, R 1 is H and R 2 is p-C6H5CH2CH3, a non-limiting chemical structure of this compound is shown in Figure 4G. In some embodiments, one, two, three, four, five or more of the compounds discussed in this paragraph (or any range derivable therein) may be excluded.

[0016] In some embodiments, R 1 is H and R 2 is H and R5 and R 6 is a bond forming a 5-membered heterocycle, X is of formula II, J 1 is OCH3, Z is H, J 2 is H and R 3 and R 4 are independently selected from H, alkyl, substituted alkyl, aryl, or R 3 and R 4 is a bond forming a 5-membered heterocycle. Various examples of such compounds are shown in Figure 5. In some particular embodiments, R 3 is CH3, R 4 is H, and a non-limiting chemical structure of this compound is shown in Figure 5A. In some particular embodiments, R 3 and R 4 is a bond forming a 5-membered heterocycle, and a non-limiting chemical structure of this compound is shown in Figure 5B. In some embodiments, one or more of the compounds discussed in this paragraph may be excluded.

[0017] In some embodiments, R 1 is H and R 2 is H and R 3 is H and R 4 is H, X is of formula II, J 1 is OCH3, Z is H, J 2 is H and R 5 and R 6 are independently selected from H, alkyl groups, substituted alkyl groups, aryl groups, or R 5 and R 6 is a bond forming a five-membered ring, or R 5 and R 6 taken together form a six-membered heterocycle. Various examples of such compounds are shown in Figure 6. In some particular embodiments, R 5 is CH3, R 6 is H, and a non-limiting chemical structure of this compound is shown in Figure 6A. In some particular embodiments, R 5 and R 6are taken together to form a six-membered heterocycle, a non-limiting chemical structure of which is shown in Figure 6B. In some embodiments, one or more of the compounds discussed in this paragraph may be excluded.

[0018] In some embodiments, R 1 is H and R 2 is H and R 3 is H and R 4 is H and R 5 and R 6 is a bond forming a 5-membered heterocycle, X is of formula V, and R 14 is H or OCH3, R 15 is H or OCH. Various examples of such compounds are shown in FIG. 7. In some particular embodiments, R 14 is OCH3, R 15 is OCH3, and a non-limiting chemical structure of this compound is shown in Figure 7A. In some particular embodiments, R 14 is OCH3, R 15 is H, and a non-limiting chemical structure of this compound is shown in Figure 7B. In some embodiments, one or more of the compounds discussed in this paragraph may be excluded.

[0019] In some embodiments, a compound having the chemical structure of Formula I can have the non-limiting chemical structure of the compound shown in Figure 18A. 1 is CH3, R 2 is CH3, R 3 is H and R 4 is H and R 5 and R 6 is a bond forming a 5-membered heterocycle, X is of formula II, J 1 is OCH3, J 2 is CH3 and Z is H, and a non-limiting chemical structure of this compound is shown in Figure 18B. 3 is H and R 4 is H and R 5 and R6 is a bond forming a 5-membered heterocycle, X is of formula II, J 1 is OCH3, and J 2 is CH3, Z is H, and R 1 and R 2 taken together form a 5-membered heterocycle, a non-limiting chemical structure of which is shown in Figure 18C. In some embodiments, R 1 is H and R 2 is H and R 3 is H and R 4 is H and R 5 and R 6 taken together form a 6-membered heterocycle, X is of formula II, and J 1 is OCH3, and J 2 is OH and Z is H, and a non-limiting chemical structure of this compound is shown in Figure 18D. 1 is H and R 2 is H and R 3 is H and R 4 is H and R 5 is CH3, R 6 is CH3, X is of formula II, J 1 is OCH3, and J 2 is OH and Z is H, and a non-limiting chemical structure of this compound is shown in Figure 18E.

[0020] Certain embodiments have formula VII The target is an AMBMP-like compound having the chemical structure of TIFF2025000907000006.tif59128. In the formula, R 1 , R 2 , R 3 , and R 4 is defined above for formula I, and R 16 and R 17 may be independently selected from H, alkyl, substituted alkyl, aryl, or R 16 and R 17 are taken together to form a 4- to 8-membered cycloalkyl or heterocyclic ring.18 can be independently alkyl, substituted alkyl, heteroalkyl, cycloalkyl, aryl, or heteroaryl. 19 can be independently alkyl, substituted alkyl, heteroalkyl, cycloalkyl, aryl, or heteroaryl. h can be 0, 1, 2, 3, or 4. k can be 1, 2, 3, 4, or 5. In some particular embodiments, R 16 and R 17 may be independently selected from H, methyl, carboxylate, carboxamide, or R 16 and R 17 taken together form a 4- to 8-membered cycloalkyl ring.

[0021] Formula VII is not Formula VI. In some embodiments, Formula VII can be Formula I. In some embodiments, a compound having the chemical structure of Formula VII can have the non-limiting chemical structure of the compound shown in FIG. 19A. In some embodiments, a compound having the chemical structure of Formula VII can have the non-limiting chemical structure of the compound shown in FIG. 19B. In some embodiments, a compound having the chemical structure of Formula VII can have the non-limiting chemical structure of the compound shown in FIG. 19C. In some embodiments, a compound having the chemical structure of Formula VII can have the non-limiting chemical structure of the compound shown in FIG. 19D. In some embodiments, a compound having the chemical structure of Formula VII can have the non-limiting chemical structure of the compound shown in FIG. 19E. In some embodiments, a compound having the chemical structure of Formula VII can have the non-limiting chemical structure of the compound shown in FIG. 19F. In some embodiments, a compound having the chemical structure of Formula VII can have the non-limiting chemical structure of the compound shown in FIG. 19G. In some embodiments, a compound having a chemical structure of Formula VII may have a non-limiting chemical structure of the compound shown in Figure 19H. In some embodiments, a compound having a chemical structure of Formula VII may have a non-limiting chemical structure of the compound shown in Figure 19I. In some embodiments, a compound having a chemical structure of Formula VII may have a non-limiting chemical structure of the compound shown in Figure 19J. In some embodiments, a compound having a chemical structure of Formula VII may have a non-limiting chemical structure of the compound shown in Figure 19K. In some embodiments, a compound having a chemical structure of Formula VII may have a non-limiting chemical structure of the compound shown in Figure 19L. In some embodiments, a compound having a chemical structure of Formula VII may have a non-limiting chemical structure of the compound shown in Figure 19M. In some embodiments, a compound having a chemical structure of Formula VII may have a non-limiting chemical structure of the compound shown in Figure 19N. In some embodiments, a compound having a chemical structure of Formula VII may have a non-limiting chemical structure of the compound shown in Figure 19O. In some embodiments, a compound having the chemical structure of Formula VII can have the non-limiting chemical structure of the compound shown in Figure 19P.

[0022] Certain embodiments are directed to compositions and methods of use of compounds having the chemical structure of Formula I and / or Formula VII, or pharma- ceutically acceptable salts or solvates thereof. Certain embodiments are directed to pharmaceutical compositions comprising an effective amount of compounds having the chemical structure of Formula I and / or Formula VII, or pharma- ceutically acceptable salts or solvates thereof. In some aspects, the pharmaceutical composition may include one or more of the compounds shown in Figures 1-7, 18, and 19, or pharma- ceutically acceptable salts or solvates thereof. In some aspects, the pharmaceutical composition may include a pharma- ceutical acceptable carrier. In some aspects, the pharmaceutical composition may include a pharma- ceutical acceptable excipient. In some embodiments, one or more of the compounds having the chemical structure of Formula I and / or Formula VII may be excluded. In some embodiments, one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty-one, thirty-one, thirty-two, thirty-three, thirty-four, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66 or more (or any range derivable therein) may be excluded.

[0023] Certain embodiments are directed to methods of treatment, comprising administering to a subject in need thereof an effective amount of a compound having the chemical structure of Formula I and / or Formula VII or a pharma- ceutically acceptable salt or solvate thereof. In some aspects, one or more of the compounds shown in Figures 1-7, 18, and 19 or a pharma- ceutically acceptable salt or solvate thereof are administered. In some aspects, the subject has been determined to have muscular dystrophy. In some particular aspects, the type of muscular dystrophy is limb-girdle muscular dystrophy. In some particular aspects, the type of muscular dystrophy is limb-girdle muscular dystrophy type 2A / R1 / D1. In some aspects, the subject has been determined to have or be at risk for muscular atrophy. In some aspects, the subject has been determined to have cachexia or sarcopenia. In some aspects, the subject has been determined to have cancer. In some aspects, the subject has been determined to have myopathy. In some embodiments, one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty-one, thirty-one, thirty-two, thirty-three, thirty-four, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66 or more (or any range derivable therein) may be excluded.

[0024] Certain embodiments are directed to a method of treating muscular dystrophy in a subject, the method comprising administering to the subject an effective amount of a compound having the chemical structure of Formula I and / or Formula VII, or a pharma- ceutically acceptable salt or solvate thereof. In some aspects, one or more of the compounds shown in Figures 1-7, 18, and 19, or a pharma- ceutically acceptable salt or solvate thereof, are administered. In some particular aspects, the type of muscular dystrophy is limb-girdle muscular dystrophy. In some particular aspects, the type of muscular dystrophy is limb-girdle muscular dystrophy type 2A. In some particular aspects, the type of muscular dystrophy is limb-girdle muscular dystrophy type R1. In some particular aspects, the type of muscular dystrophy is limb-girdle muscular dystrophy type D1. In some embodiments, one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty-one, thirty-one, thirty-two, thirty-three, thirty-four, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66 or more (or any range derivable therein) may be excluded. In some cases, the methods inhibit and / or reduce symptoms or complications of muscular dystrophy by at least, at most, or exactly 100%, 99%, 98%, 96%, 94%, 92%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 40%, 30%, 20%, 10%, or 5%, or any range derivable therein.

[0025] Certain embodiments are directed to a method of treating muscle atrophy in a subject, the method comprising administering to the subject an effective amount of a compound having a chemical structure of Formula I and / or Formula VII, or a pharma- ceutically acceptable salt or solvate thereof. In some aspects, one or more of the compounds shown in Figures 1-7, 18, and 19, or a pharma- ceutically acceptable salt or solvate thereof, are administered. In some aspects, the subject has been determined to have muscle atrophy or to be at risk for muscle atrophy. In some embodiments, the subject has been tested for muscle atrophy, or a disease that causes or is associated with muscle atrophy. In some embodiments, the subject has been previously treated with one or more treatments for muscle atrophy. In some embodiments, one or more of the treatments for muscle atrophy is prescribed chemotherapy. In some embodiments, one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty-one, thirty-one, thirty-two, thirty-three, thirty-four, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66 or more (or any range derivable therein) may be excluded. In some cases, the methods inhibit and / or reduce symptoms or complications of muscle atrophy by at least, at most, or exactly 100%, 99%, 98%, 96%, 94%, 92%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 40%, 30%, 20%, 10%, or 5%, or any range derivable therein.

[0026] Certain embodiments are directed to a method for treating cachexia or sarcopenia in a subject, the method comprising administering to the subject an effective amount of a compound having a chemical structure of Formula I and / or Formula VII, or a pharma- ceutically acceptable salt or solvate thereof. In some aspects, one or more of the compounds shown in Figures 1-7, 18, and 19, or a pharma- ceutically acceptable salt or solvate thereof, are administered. In some embodiments, the subject has been diagnosed with cancer. In some embodiments, the subject is prescribed bed rest. In some embodiments, the subject has been diagnosed with age-related sarcopenia. In some embodiments, one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty-one, thirty-one, thirty-two, thirty-three, thirty-four, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66 or more (or any range derivable therein) may be excluded. In some cases, the methods inhibit and / or reduce symptoms or complications of cachexia or sarcopenia by at least, at most, or exactly 100%, 99%, 98%, 96%, 94%, 92%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 40%, 30%, 20%, 10%, or 5%, or any range derivable therein.

[0027] Certain embodiments are directed to a method of increasing muscle mass in a subject or treating a disease associated with loss of muscle mass in a subject, the method comprising administering to the subject an effective amount of a compound having the chemical structure of Formula I and / or Formula VII, or a pharma- ceutically acceptable salt or solvate thereof. In some aspects, one or more of the compounds shown in Figures 1-7, 18, and 19, or a pharma- ceutically acceptable salt or solvate thereof, are administered. In some embodiments, one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty-one, thirty-two, thirty-three, thirty-four ...six, twenty-six, twenty-six, twenty-six, twenty-six, twenty-six, twenty-six, twenty-six, twenty-six, twenty-six, twenty-six, twenty-six, twenty-six, twenty-six, twenty-six, twenty-six, twenty-six, twenty-six, twenty-six, twenty-six, twenty-six, twenty-six, twenty-six, twenty-six, twenty-six, twenty-six, twenty-six, twenty-six, twenty-six, twenty- 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66 or more (or any range derivable therein) may be excluded. In some cases, the percentage increase in muscle mass is 10000%, 1000%, 500%, 200%, 100%, 99%, 98%, 96%, 94%, 92%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 40%, 30%, 20%, 10%, or 5%, or any range derivable therein.

[0028] Certain embodiments are directed to a method of increasing oxidative metabolism in a subject or treating a disease associated with decreased oxidative metabolism in a subject, comprising administering to the subject an effective amount of a compound having the chemical structure of Formula I and / or Formula VII, or a pharma- ceutically acceptable salt or solvate thereof. In some aspects, one or more of the compounds shown in Figures 1-7, 18, and 19, or a pharma-ceutically acceptable salt or solvate thereof, are administered. In some embodiments, one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty-one, thirty-one, thirty-two, thirty-three, thirty-four, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66 or more (or any range derivable therein) may be excluded. In some cases, the percentage increase in oxidative metabolism is 10000%, 1000%, 500%, 200%, 100%, 99%, 98%, 96%, 94%, 92%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 40%, 30%, 20%, 10%, or 5%, or any range derivable therein.

[0029] Certain embodiments are directed to a method of improving muscle strength in a subject or treating a disease associated with reduced muscle strength in a subject, the method comprising administering to the subject an effective amount of a compound having the chemical structure of Formula I and / or Formula VII, or a pharma- ceutically acceptable salt or solvate thereof. In some aspects, one or more of the compounds shown in Figures 1-7, 18, and 19, or a pharma- ceutically acceptable salt or solvate thereof, are administered. In some embodiments, one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty-one, thirty-two, thirty-three, thirty-four ...six, twenty-six, twenty-six, twenty-six, twenty-six, twenty-six, twenty-six, twenty-six, twenty-six, twenty-six, twenty-six, twenty-six, twenty-six, twenty-six, twenty-six, twenty-six, twenty-six, twenty-six, twenty-six, twenty-six, twenty-six, twenty-six, twenty-six, twenty-six, twenty-six, twenty-six, twenty-six, twenty-six, twenty-six, twenty-s 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66 or more (or any range derivable therein) may be excluded. In some cases, the percentage strength improvement is 10000%, 1000%, 500%, 200%, 100%, 99%, 98%, 96%, 94%, 92%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 40%, 30%, 20%, 10%, or 5%, or any range derivable therein.

[0030] Certain embodiments are directed to a method of improving muscle function in a subject or treating a disease associated with a decline in muscle function in a subject, comprising administering to the subject an effective amount of a compound having the chemical structure of Formula I and / or Formula VII, or a pharma- ceutically acceptable salt or solvate thereof. In some aspects, one or more of the compounds shown in Figures 1-7, 18, and 19, or a pharma-ceutically acceptable salt or solvate thereof, are administered. In some embodiments, one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty-one, thirty-one, thirty-two, thirty-three, thirty-four, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66 or more (or any range derivable therein) may be excluded. In some cases, the improvement in muscle function is 10000%, 1000%, 500%, 200%, 100%, 99%, 98%, 96%, 94%, 92%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 40%, 30%, 20%, 10%, or 5%, or any range derivable therein.

[0031] Certain embodiments are directed to a method of reducing the number of degenerated muscle fibers in a subject or treating a disease associated with an increase in degenerated muscle fibers in a subject, comprising administering to the subject an effective amount of a compound having the chemical structure of Formula I and / or Formula VII, or a pharma- ceutically acceptable salt or solvate thereof. In some aspects, one or more of the compounds shown in Figures 1-7, 18, and 19, or a pharma- ceutically acceptable salt or solvate thereof, are administered. In some embodiments, one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty-one, thirty-one, thirty-two, thirty-three, thirty-four, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66 or more (or any range derivable therein) may be excluded. In some cases, the reduction in the number of degenerated muscle fibers is at least or at most or exactly 100%, 99%, 98%, 96%, 94%, 92%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 40%, 30%, 20%, 10%, or 5%, or any range derivable therein.

[0032] Certain embodiments are directed to a method of increasing the number of regenerated muscle fibers in a subject or treating a disease associated with a decrease in regenerated muscle fibers in a subject, the method comprising administering to the subject an effective amount of a compound having the chemical structure of Formula I and / or Formula VII, or a pharma- ceutically acceptable salt or solvate thereof. In some aspects, one or more of the compounds shown in Figures 1-7, 18, and 19, or a pharma- ceutically acceptable salt or solvate thereof, are administered. In some embodiments, one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty-one, thirty-one, thirty-two, thirty-three, thirty-four, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66 or more (or any range derivable therein) may be excluded. In some cases, the percentage increase in the number of regenerated muscle fibers is 10,000%, 1,000%, 500%, 200%, 100%, 99%, 98%, 96%, 94%, 92%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 40%, 30%, 20%, 10%, or 5%, or any range derivable therein.

[0033] Certain embodiments are directed to a method of increasing expression of at least one gene selected from the group consisting of myosin light chain 2, myosin XVIIIb, myomesin 3, lipoprotein lipase, patatin-like phospholipase domain-containing 2, and sarcomeric mitochondrial creatine kinase in a subject, the method comprising administering to the subject an effective amount of a compound having the chemical structure of Formula I and / or Formula VII, or a pharma- ceutically acceptable salt or solvate thereof. In some aspects, one or more of the compounds depicted in Figures 1-7, 18, and 19, or a pharma-ceutically acceptable salt or solvate thereof, are administered. In some embodiments, one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty-one, thirty-one, thirty-two, thirty-three, thirty-four, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66 or more (or any range derivable therein) may be excluded. In some cases, the percentage increase in expression of at least one gene is 10000%, 1000%, 500%, 200%, 100%, 99%, 98%, 96%, 94%, 92%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 40%, 30%, 20%, 10%, or 5%, or any range derivable therein.

[0034] Certain embodiments are directed to a method of treating a disease associated with decreased expression of at least one gene selected from the group consisting of myosin light chain 2, myosin XVIIIb, myomesin 3, lipoprotein lipase, patatin-like phospholipase domain-containing 2, and sarcomeric mitochondrial creatine kinase in a subject, the method comprising administering to the subject an effective amount of a compound having the chemical structure of Formula I and / or Formula VII, or a pharma- ceutically acceptable salt or solvate thereof. In some aspects, one or more of the compounds depicted in Figures 1-7, 18, and 19, or a pharma-ceutically acceptable salt or solvate thereof, are administered. In some embodiments, one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty-one, thirty-one, thirty-two, thirty-three, thirty-four, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66 or more (or any range derivable therein) may be excluded. In some cases, the methods inhibit and / or reduce symptoms or complications of the disease by at least, at most, or exactly 100%, 99%, 98%, 96%, 94%, 92%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 40%, 30%, 20%, 10%, or 5%, or any range derivable therein.

[0035] Certain embodiments are directed to a method for treating a myopathy in a subject, the method comprising administering to the subject an effective amount of a compound having a chemical structure of Formula I and / or Formula VII, or a pharma- ceutically acceptable salt or solvate thereof. In some aspects, one or more of the compounds shown in Figures 1-7, 18, and 19, or a pharma- ceutically acceptable salt or solvate thereof, are administered. Myopathies include, for example, diseases resulting from mutations in the ryanodine receptor and / or the dihydropyridine receptor (DHPR), as well as nemaline myopathy. In some embodiments, the method is for treating nemaline myopathy. Other examples of myopathies are those described herein. In some embodiments, one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty-one, thirty-one, thirty-two, thirty-three, thirty-four, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66 or more (or any range derivable therein) may be excluded. In some cases, the methods inhibit and / or reduce myopathic symptoms or complications by at least, at most, or exactly 100%, 99%, 98%, 96%, 94%, 92%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 40%, 30%, 20%, 10%, or 5%, or any range derivable therein.

[0036] In some embodiments, the muscle mass of the subject is increased compared to the muscle mass before administration of the compound having the chemical structure of Formula I and / or Formula VII, or a pharma- ceutical acceptable salt or solvate thereof. In some embodiments, the muscle strength of the subject is increased compared to the muscle strength before administration of the compound having the chemical structure of Formula I and / or Formula VII, or a pharma- ceutical acceptable salt or solvate thereof. In some embodiments, the muscle function of the subject is improved compared to the muscle function before administration of the compound having the chemical structure of Formula I and / or Formula VII, or a pharma- ceutical acceptable salt or solvate thereof. In some embodiments, the number of degenerated muscle fibers in the subject is decreased compared to the number of degenerated muscle fibers in the subject before administration of the compound having the chemical structure of Formula I and / or Formula VII, or a pharma- ceutical acceptable salt or solvate thereof. In some embodiments, the number of regenerated muscle fibers in the subject is increased compared to the number of regenerated muscle fibers in the subject before administration of the compound having the chemical structure of Formula I and / or Formula VII, or a pharma- ceutical acceptable salt or solvate thereof. In some aspects, one or more of the compounds shown in Figures 1-7, 18, and 19, or pharma- ceutical acceptable salts or solvates thereof, are administered. In some embodiments, one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty-one, thirty-one, thirty-two, thirty-three, thirty-four, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66 or more (or any range derivable therein) may be excluded.In some cases, the percentage increase in muscle mass is 10000%, 1000%, 500%, 200%, 100%, 99%, 98%, 96%, 94%, 92%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 40%, 30%, 20%, 10%, or 5%, or any range derivable therein.

[0037] In some embodiments, the expression of at least one gene selected from the group consisting of myosin light chain 2, myosin XVIIIb, myomesin 3, lipoprotein lipase, patatin-like phospholipase domain-containing 2, and sarcomeric mitochondrial creatine kinase is increased compared to the expression of the gene prior to administration of a compound having the chemical structure of Formula I and / or Formula VII, or a pharma- ceutically acceptable salt or solvate thereof. In some aspects, one or more of the compounds shown in Figures 1-7, 18, and 19, or a pharma- ceutically acceptable salt or solvate thereof, are administered. In some embodiments, the method further comprises measuring or determining the expression level of at least one gene selected from the group consisting of myosin light chain 2, myosin XVIIIb, myomesin 3, lipoprotein lipase, patatin-like phospholipase domain-containing 2, and sarcomeric mitochondrial creatine kinase. In some embodiments, one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty-one, thirty-one, thirty-two, thirty-three, thirty-four, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66 or more (or any range derivable therein) may be excluded. In some cases, the percentage increase in expression of at least one gene is 10000%, 1000%, 500%, 200%, 100%, 99%, 98%, 96%, 94%, 92%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 40%, 30%, 20%, 10%, or 5%, or any range derivable therein.

[0038] In some embodiments, the subject is a human. In some embodiments, the subject has a mutation in the calpain 3 gene. In some embodiments, the subject has been determined to have a mutation in the calpain 3 gene. In some embodiments, the sequence of all or part of the subject's calpain 3 gene is determined. In some embodiments, the method further comprises determining whether the subject's calpain 3 gene is mutated. In some embodiments, the subject is not being treated for a gastrointestinal disease or condition with lansoprazole or rabeprazole. In some embodiments, the subject is not suffering from any symptoms of a gastrointestinal disease or condition at the time lansoprazole or rabeprazole is administered. In some embodiments, the subject has been diagnosed with a myopathy as described herein. In some embodiments, the subject has been determined to have a deficiency in CaMKII. The deficiency can be determined by measuring CaMKII activity or expression, or by determining CaMKII signaling activity or expression (expression or activity of downstream targets) or CaMKII-dependent gene expression. In some embodiments, the method further comprises determining CaMKII expression level or activity level. Gene and / or protein expression or activity levels can be determined by methods known in the art, such as, for example, performing fluorescent in situ hybridization (FISH), comparative genomic hybridization (CGH), real-time PCR, Southern blot, or Western blot analysis, etc. Other applicable methods are known in the art and / or described herein.

[0039] In some embodiments, the route of administration is oral, parenteral, subcutaneous, intraperitoneal, or intramuscular. In some embodiments, the compound having the chemical structure of Formula I and / or Formula VII, or a pharma- ceutically acceptable salt or solvate thereof, is administered topically. In some embodiments, the compound having the chemical structure of Formula I and / or Formula VII, or a pharma- ceutically acceptable salt or solvate thereof, is administered to muscle tissue. In some embodiments, the compound having the chemical structure of Formula I and / or Formula VII, or a pharma- ceutically acceptable salt or solvate thereof, is administered multiple times. In some aspects, an effective amount of a compound having a chemical structure as shown in FIG. 1A, or a pharma- ceutically acceptable salt or solvate thereof, is administered. In some aspects, an effective amount of a compound having a chemical structure as shown in FIG. 1B, or a pharma- ceutically acceptable salt or solvate thereof, is administered. In some aspects, an effective amount of a compound having a chemical structure as shown in FIG. 1C, or a pharma- ceutically acceptable salt or solvate thereof, is administered. In some embodiments, a compound having a chemical structure as shown in FIG. 1D or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 1E or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 1F or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 1G or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 1H or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 1I or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 1J or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 1K or a pharma- ceutical acceptable salt or solvate thereof is administered in an effective amount.In some embodiments, a compound having a chemical structure as shown in FIG. 1L or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 1M or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 1N or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 1O or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 1P or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 1Q or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 1R or a pharma- ceutical acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 1S or a pharma- ceutical acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 1T or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 1U or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 1V or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 1W or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 1X or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 1Y or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 1Z or a pharma- ceutical acceptable salt or solvate thereof is administered in an effective amount.In some embodiments, a compound having a chemical structure as shown in FIG. 1AA or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 1BB or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 2A or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 2B or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 2C or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 3 or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 4A or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 4B or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 4C or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 4D or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 4E or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 4F or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 4G or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 5A or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 5B or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount.In some embodiments, a compound having a chemical structure as shown in FIG. 6A or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 6B or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 7A or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 7B or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 18A or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 18B or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 18C or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 18D or a pharma- ceutical acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 18E or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 19A or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 19B or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 19C or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 19D or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 19E or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 19F or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount.In some embodiments, a compound having a chemical structure as shown in FIG. 19G or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 19H or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 19I or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 19J or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 19K or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 19L or a pharma- ceutically acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, a compound having a chemical structure as shown in FIG. 19M or a pharma- ceutical acceptable salt or solvate thereof is administered in an effective amount. In some embodiments, an effective amount of a compound having a chemical structure as shown in Figure 19N or a pharma- ceutically acceptable salt or solvate thereof is administered. In some embodiments, an effective amount of a compound having a chemical structure as shown in Figure 19O or a pharma- ceutically acceptable salt or solvate thereof is administered. In some embodiments, an effective amount of a compound having a chemical structure as shown in Figure 19P or a pharma- ceutically acceptable salt or solvate thereof is administered. In some embodiments, a combination of compounds of the present disclosure is administered. In some embodiments, one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty-one, thirty-two, thirty-three, thirty-four, thirty-five, thirty-six, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66 or more (or any range derivable therein) may be excluded.

[0040] Other embodiments are directed to any of the compounds shown in Figures 1-7, 18, and 19. In some embodiments, one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty-one, thirty-one, thirty-two, thirty-three, thirty-four, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty-one, thirty-two, thirty-three, thirty-four, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty-one, thirty-two, thirty-three, thirty-four, twenty-six, twenty-seven, twenty-six ... 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66 or more (or any range derivable therein) may be excluded.

[0041] In the present context, at least the following 62 embodiments are disclosed: The target compound has the chemical structure of TIFF2025000907000007.tif63128. In the formula, R 1 and R 2 are independently H, alkyl, substituted alkyl, aryl, or R 1 and R 2 together form a 4- to 6-membered heterocyclic ring; R 3 and R 4 are independently selected from H, alkyl, substituted alkyl, aryl, or R 3 and R 4 is a bond forming a 5-membered heterocyclic ring, or R 3 and R 4 together form a six-membered heterocyclic ring; R 5 and R 6 are independently selected from H, alkyl, substituted alkyl, aryl, or R 5 and R 6 is a bond forming a 5-membered heterocyclic ring, or R 5 and R 6taken together form a six-membered heterocycle; X is a group having the chemical structure of Formula II, Formula III, Formula IV, or Formula V: TIFF2025000907000008.tif49128In the formula, Z is H, alkyl, substituted alkyl, aryl, OR 7 , or N.R. 8 R 9 ;R 7 is H, alkyl, haloalkyl, substituted alkyl, or aryl; R 8 and R 9 are independently H, alkyl, substituted alkyl, aryl, or R 8 and R 9 together form a 4- to 6-membered heterocycle, J 1 is H, alkyl, or OR 10 Selected from; R 10 is H, alkyl, haloalkyl, substituted alkyl, aryl, or ((CH2) n O) p CH2CH2R 11 (n is 1, 2, or 3; p is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10); R 11 is OH, NH2, or alkoxy; J 2 is H, alkyl, or OR 12 Selected from; R 12 is H, alkyl, haloalkyl, substituted alkyl, aryl, or ((CH2) n O) p CH2CH2R 13 (n is 1, 2, or 3; p is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10); R 13 is OH, NH2, or alkoxy; TIFF2025000907000009.tif25128 where M is O, NH, or CH2; TIFF2025000907000010.tif83128 in formula, R 14 is H or alkoxy, R 15 is H or alkoxy; Formula I is not Formula VI below. TIFF2025000907000011.tif48128

[0042] Embodiment 2 is directed to a compound according to embodiment 1, wherein R 1 is H and R 2 is H and R 3 is H and R 4 is H and R 5 and R 6 is a bond forming a 5-membered heterocycle, and X is of formula II. Embodiment 3 is directed to compounds according to embodiment 1, wherein R 1 is H and R 2 is H and R 3 is H and R 4 is H and R 5 and R 6 is a bond forming a 5-membered heterocycle, X is of formula II, Z is H, and J 2 is H and J 1 OR 10 Embodiment 4 is directed to compounds according to embodiment 3, wherein R 10is H, CF3, CH2CH3, CH(CH3)2, CH2CH2CH3, CH2CH2OCH3, CH2CH2OCH2CH2NH2, CH2CH2OCH2CH2OCH2CH2OCH3, CH2NH2, CH2CH2NH2, or CH2CONH2. Embodiment 5 is directed to a compound of any one of embodiments 1-4, wherein the compound further comprises a pharma- ceutically acceptable carrier. Embodiment 6 is directed to a method of treating muscular dystrophy in a subject, the method comprising administering to the subject an effective amount of a compound of any one of embodiments 1-4, or a pharma- ceutically acceptable salt or solvate thereof. Embodiment 7 is directed to a method of embodiment 6, wherein the type of muscular dystrophy is limb-girdle muscular dystrophy. Embodiment 8 is directed to a method of embodiment 6, wherein the type of muscular dystrophy is limb-girdle muscular dystrophy type 2A / R1 / D1. Embodiment 9 is directed to a method of treating muscle atrophy in a subject, the method comprising administering to the subject an effective amount of a compound according to any one of embodiments 1-4 or a pharma- ceutically acceptable salt or solvate thereof. Embodiment 10 is directed to a method according to embodiment 9, the subject has been determined to have muscle atrophy or to be at risk for muscle atrophy. Embodiment 11 is directed to a method according to any one of embodiments 9-10, the subject has been tested for muscle atrophy or a disease that causes muscle atrophy or is associated with muscle atrophy. Embodiment 12 is directed to a method according to any one of embodiments 9-11, the subject has previously been treated with one or more treatments for muscle atrophy. Embodiment 13 is directed to a method according to embodiment 12, the one or more treatments for muscle atrophy is prescribed chemotherapy. Embodiment 14 is directed to a method for treating cachexia or sarcopenia in a subject, the method comprising administering to the subject an effective amount of a compound according to any one of embodiments 1-4 or a pharma- ceutically acceptable salt or solvate thereof. Embodiment 15 is directed to a method according to embodiment 14, wherein the subject has been diagnosed with cancer.Embodiment 16 is directed to a method according to any one of embodiment 14 or embodiment 15, wherein the subject is advised to remain on bed rest.Embodiment 17 is directed to a method according to any one of embodiments 14-16, wherein the subject has been diagnosed with age-related sarcopenia. Embodiment 18 is directed to a method of increasing muscle mass in a subject, comprising administering to the subject an effective amount of a compound according to any one of embodiments 1-4, or a pharma- ceutically acceptable salt or solvate thereof. Embodiment 19 is directed to a method of improving muscle strength in a subject, comprising administering to the subject an effective amount of a compound according to any one of embodiments 1-4, or a pharma- ceutically acceptable salt or solvate thereof. Embodiment 20 is directed to a method of improving muscle function in a subject, comprising administering to the subject an effective amount of a compound according to any one of embodiments 1-4, or a pharma- ceutically acceptable salt or solvate thereof. Embodiment 21 is directed to a method of reducing the number of degenerated muscle fibers in a subject, comprising administering to the subject an effective amount of a compound according to any one of embodiments 1-4, or a pharma- ceutically acceptable salt or solvate thereof. Embodiment 22 is directed to a method of increasing the number of regenerated muscle fibers in a subject, the method comprising administering to the subject an effective amount of a compound according to any one of embodiments 1-4, or a pharma- ceutically acceptable salt or solvate thereof. Embodiment 23 is directed to a method of increasing expression of at least one gene selected from the group consisting of myosin light chain 2, myosin XVIIIb, myomesin 3, lipoprotein lipase, patatin-like phospholipase domain-containing 2, and sarcomeric mitochondrial creatine kinase in a subject, the method comprising administering to the subject an effective amount of a compound according to any one of embodiments 1-4, or a pharma- ceutically acceptable salt or solvate thereof. Embodiment 24 is directed to a method according to any one of embodiments 6-23, the subject having a mutation in the calpain 3 gene. Embodiment 25 is directed to a method according to any one of embodiments 6-24, the subject having been determined to have a deficiency in CaMKII. Embodiment 26 is directed to a method according to any one of embodiments 6-25, the method further comprising determining the expression or activity level of CaMKII.Embodiment 27 is directed to a method according to any one of embodiments 6-26, wherein the compound is administered orally, parenterally, subcutaneously, intraperitoneally, or intramuscularly. Embodiment 28 is directed to a method according to any one of embodiments 6-27, wherein the compound is administered topically. Embodiment 29 is directed to a method according to embodiment 28, wherein the compound is administered to muscle tissue. Embodiment 30 is directed to a method according to any one of embodiments 6-29, wherein the subject is a human.

[0043] Embodiment 31 is a compound of formula VII The target compound has the chemical structure of TIFF2025000907000012.tif59128. During the ceremony R 1 and R 2 are independently H, alkyl, substituted alkyl, aryl, or R 1 and R 2 together form a 4- to 6-membered heterocyclic ring; R 3 and R 4 are independently selected from H, alkyl, substituted alkyl, aryl, or R 3 and R 4 is a bond forming a 5-membered heterocyclic ring, or R 3 and R 4 together form a six-membered heterocyclic ring; R 16 and R 17 are independently selected from H, alkyl, substituted alkyl, aryl, or R 16 and R 17 together form a 4- to 8-membered cycloalkyl or heterocyclic ring; each R 18 is independently alkyl, substituted alkyl, heteroalkyl, cycloalkyl, aryl, or heteroaryl; each R 19 is independently alkyl, substituted alkyl, heteroalkyl, cycloalkyl, aryl, or heteroaryl; h is 0, 1, 2, 3, or 4; k is 1, 2, 3, 4, or 5; Formula VII is a compound of Formula VI Not TIFF2025000907000013.tif49128. Embodiment 32 is directed to a compound according to embodiment 31, wherein the compound has formula I TIFF2025000907000014.tif63128, In the formula, R 1 and R 2 are independently H, alkyl, substituted alkyl, aryl, or R 1 and R 2 together form a 4- to 6-membered heterocyclic ring; R 3 and R 4 are independently selected from H, alkyl, substituted alkyl, aryl, or R 3 and R 4 is a bond forming a 5-membered heterocyclic ring, or R 3 and R 4 together form a six-membered heterocyclic ring; R 5 and R 6 are independently selected from H, alkyl, substituted alkyl, aryl, or R 5 and R 6 is a bond forming a 5-membered heterocyclic ring, or R 5 and R 6 taken together form a six-membered heterocycle; X is a group having the chemical structure of Formula II, Formula III, Formula IV, or Formula V: TIFF2025000907000015.tif52128 where Z is H, alkyl, substituted alkyl, aryl, OR 7 , or N.R. 8 R 9 ;R 7 is H, alkyl, haloalkyl, substituted alkyl, or aryl; R 8 and R 9 are independently H, alkyl, substituted alkyl, aryl, or R 8 and R 9 together form a 4- to 6-membered heterocycle, J 1 is H, alkyl, or OR 10 Selected from; R 10is H, alkyl, haloalkyl, substituted alkyl, aryl, or ((CH2) n O) p CH2CH2R 11 (n is 1, 2, or 3; p is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10); R 11 is OH, NH2, or alkoxy; J 2 is H, alkyl, or OR 12 Selected from; R 12 is H, alkyl, haloalkyl, substituted alkyl, aryl, or ((CH2) n O) p CH2CH2R 13 (n is 1, 2, or 3; p is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10); R 13 is OH, NH2, or alkoxy; TIFF2025000907000016.tif25128 where M is O, NH, or CH2; TIFF2025000907000017.tif87128 formula, R 14 is H or alkoxy, R 15 is H or alkoxy. Embodiment 33 is directed to compounds according to embodiment 32, wherein R 1 is H and R 2 is H and R 3 is H and R 4 is H and R 5 and R 6 is a bond forming a 5-membered heterocycle, and X is of formula II. Embodiment 34 is directed to compounds according to embodiment 32, wherein R 1 is H and R 2 is H and R 3 is H and R 4 is H and R 5 and R 6 is a bond forming a 5-membered heterocycle, X is of formula II, Z is H, and J 2 is H and J 1 OR 10Embodiment 35 is directed to compounds according to embodiment 34, wherein R 10is H, CF3, CH2CH3, CH(CH3)2, CH2CH2CH3, CH2CH2OCH3, CH2CH2OCH2CH2NH2, CH2CH2OCH2CH2OCH2CH2OCH3, CH2NH2, CH2CH2NH2, or CH2CONH2.Embodiment 36 is directed to a compound according to embodiment 31, wherein the compound is any one of the compounds according to Figures 1 to 7, 18, and 19, and is selected from the group consisting of AMBMP analog 1, AMBMP analog 2, AMBMP analog 3, AMBMP analog 4, AMBMP analog 5, AMBMP analog 6, AMBMP analog 7, AMBMP analog 8, AMBMP analog 9, AMBMP analog 10, AMBMP analog 11, AMBMP analog 12, AMBMP analog 13, AMBMP analog 14, AMBMP analog 15, AMBMP analog 16, AMBMP analog 17, AMBMP analog 18, AMBMP analog 19, AMBMP analog 20, AMBMP analog 21, AMBMP analog 22, AMBMP analog 23, AMBMP analog 24, AMBMP analog 25, AMBMP analog 26, AMBMP analog 27, AMBMP analog 28, AMBMP analog 29, AMBMP analog 30, AMBMP analog 31, AMBMP analog 32, AMBMP analog 33, AMBMP analog 34, AMBMP analog 35, AMBMP analog 36, AMBMP analog 37, AMBMP analog 38, AMBMP analog 39, AMBMP analog 40, AMBMP analog 41, AMBMP analog 42, AMBMP analog 43, AMBMP analog 44, AMBMP analog 45, AMBMP analog 46, AMBMP analog 47, AMBMP analog 48, AMBMP analog 49, AMBMP analog 50, AMBMP analog 51, AMBMP analog 52, AMBMP analog 53, AMBMP analog 54, AMBMP analog 55, AMBMP analog 56, AMBMP analog 57, AMBMP analog 58, AMBMP analog BMP analog 17, AMBMP analog 18, AMBMP analog 19, AMBMP analog 20, AMBMP analog 21, AMBMP analog 22, AMBMP analog 23, AMBMP analog 24, AMBMP analog 25, AMBMP analog 26, AMBMP analog 27 , AMBMP analog 28, AMBMP analog 29, AMBMP analog 30, AMBMP analog 31, AMBMP analog 32, AMBMP analog 33, AMBMP analog 34, AMBMP analog 35, AMBMP analog 36, AMBMP analog 37, AMBMP analog body 38, AMBMP analog 39, AMBMP analog 40, AMBMP analog 41, AMBMP analog 42, AMBMP analog 43, AMBMP analog 44, AMBMP analog 45, AMBMP analog 46, AMBMP analog 47, AMBMP analog 48, AMBM P analogue 49, AMBMP analogue 50, AMBMP analogue 51, AMBMP analogue 52, AMBMP analogue 53, AMBMP analogue 54, AMBMP analogue 55, AMBMP analogue 56, AMBMP analogue 57, AMBMP analogue 58, AMBMP analogue 59, A Such as any one of MBMP analog 60, AMBMP analog 61, AMBMP analog 62, AMBMP analog 63, AMBMP analog 64, AMBMP analog 65, AMBMP analog 66, such as any one of AMBMP analog 1, AMBMP analog 2, AMBMP analog 3, AMBMP analog 4, AMBMP analog 5, AMBMP analog 6, AMBMP analog 8, AMBMP analog 17, AMBMP analog 21, AMBMP analog 25, AMBMP analog 38, AMBMP analog 39, or AMBMP analog 40.Embodiment 37 is directed to a composition comprising a compound of any one of embodiments 31-36, the composition further comprising a pharma- ceutically acceptable carrier. Embodiment 38 is directed to a method of treating muscular dystrophy in a subject, the method comprising administering to the subject an effective amount of a compound of any one of embodiments 31-36, or a pharma- ceutically acceptable salt or solvate thereof. Embodiment 39 is directed to a method of embodiment 38, the type of muscular dystrophy is limb-girdle muscular dystrophy. Embodiment 39 is directed to a method of embodiment 38, the type of muscular dystrophy is limb-girdle muscular dystrophy type 2A / R1 / D1. Embodiment 40 is directed to a method of treating muscular atrophy in a subject, the method comprising administering to the subject an effective amount of a compound of any one of embodiments 31-36, or a pharma- ceutically acceptable salt or solvate thereof. Embodiment 42 is directed to a method of embodiment 41, the subject has been determined to have or be at risk for muscular atrophy. Embodiment 43 is directed to a method according to any one of embodiments 41-42, wherein the subject is being tested for muscle atrophy or a disease that causes or is associated with muscle atrophy. Embodiment 44 is directed to a method according to any one of embodiments 41-43, wherein the subject has previously been treated with one or more treatments for muscle atrophy. Embodiment 45 is directed to a method according to embodiment 44, wherein the one or more treatments for muscle atrophy are prescribed chemotherapy. Embodiment 46 is directed to a method for treating cachexia or sarcopenia in a subject, comprising administering to the subject an effective amount of a compound according to any one of embodiments 31-36, or a pharma- ceutically acceptable salt or solvate thereof. Embodiment 47 is directed to a method according to embodiment 46, wherein the subject has been diagnosed with cancer. Embodiment 48 is directed to a method according to embodiment 46 or embodiment 47, wherein the subject is prescribed bed rest. Embodiment 49 is directed to a method according to any one of embodiments 46 to 48, wherein the subject has been diagnosed with age-related sarcopenia.Embodiment 50 is directed to a method of increasing muscle mass in a subject, the method comprising administering to the subject an effective amount of a compound according to any one of embodiments 31-36, or a pharma- ceutically acceptable salt or solvate thereof. Embodiment 51 is directed to a method of improving muscle strength in a subject, the method comprising administering to the subject an effective amount of a compound according to any one of embodiments 31-36, or a pharma- ceutically acceptable salt or solvate thereof. Embodiment 52 is directed to a method of improving muscle function in a subject, the method comprising administering to the subject an effective amount of a compound according to any one of embodiments 31-36, or a pharma- ceutically acceptable salt or solvate thereof. Embodiment 53 is directed to a method of reducing the number of degenerated muscle fibers in a subject, the method comprising administering to the subject an effective amount of a compound according to any one of embodiments 31-36, or a pharma- ceutically acceptable salt or solvate thereof. Embodiment 54 is directed to a method of increasing the number of regenerated muscle fibers in a subject, the method comprising administering to the subject an effective amount of a compound according to any one of embodiments 31-36, or a pharma- ceutically acceptable salt or solvate thereof. Embodiment 55 is directed to a method of increasing expression of at least one gene selected from the group consisting of myosin light chain 2, myosin XVIIIb, myomesin 3, lipoprotein lipase, patatin-like phospholipase domain-containing 2, and sarcomeric mitochondrial creatine kinase in a subject, the method comprising administering to the subject an effective amount of a compound of any one of embodiments 31-36, or a pharma- ceutically acceptable salt or solvate thereof. Embodiment 56 is directed to a method of any one of embodiments 38-55, the subject having a mutation in the calpain 3 gene. Embodiment 57 is directed to a method of any one of embodiments 38-56, the subject having been determined to have a deficiency in CaMKII. Embodiment 58 is directed to a method of any one of embodiments 38-57, the method further comprising determining the expression or activity level of CaMKII.Embodiment 59 is directed to a method according to any one of embodiments 38-58, wherein the compound is administered orally, parenterally, subcutaneously, intraperitoneally, or intramuscularly. Embodiment 60 is directed to a method according to any one of embodiments 38-59, wherein the compound is administered topically. Embodiment 61 is directed to a method according to embodiment 60, wherein the compound is administered to muscle tissue. Embodiment 62 is directed to a method according to any one of embodiments 38-61, wherein the subject is a human.

[0044] "Subject", "individual", or "patient" are used interchangeably herein and refer to a vertebrate (e.g., a primate, a mammal, or a human). Mammals include, but are not limited to, horses, dogs, cows, sheep, mice, rats, monkeys, humans, farm animals, sport animals, and pets. Subjects participating in any clinical research trial or involved in an epidemiological study or used as controls who do not show any clinical signs of disease are also intended to be included as subjects.

[0045] The term "comprising" as used herein is intended to mean that the compositions and methods include the recited elements but do not exclude other elements. "Consisting essentially of," when used in the definition of compositions and methods, is intended to mean excluding other elements that have any essential importance to the combination for the purposes of the description. "Consisting essentially of," in the context of pharmaceutical compositions of the present disclosure, is intended to include all of the recited active agents and exclude any additional active agents not recited, but not exclude other composition components that are not active ingredients. Thus, it follows that a composition consisting essentially of the elements defined herein does not exclude trace contaminants from the isolation and purification methods, as well as pharma- ceutical acceptable carriers (such as phosphate buffered saline, preservatives, and the like). "Consisting of" is intended to mean excluding non-negligible amounts of other component elements and other substantial method steps for administering the compositions of the present invention or other process steps for obtaining the compositions or achieving the intended results. The scope of the present invention includes embodiments defined by each of these transition terms.

[0046] The terms "improving," "inhibiting," or "reducing," or any variation of these terms, as used in the claims and / or this specification, include any measurable decrease or complete inhibition to achieve a desired result.

[0047] As used herein, "treating," "treatment," or "therapy" is an approach for obtaining beneficial or desired clinical results. This includes the alleviation of symptoms, or any suitable result described throughout this disclosure, including the examples. Moreover, such terms are intended to encompass curing as well as the amelioration of at least one symptom of a condition or disease.

[0048] The use of one or more compositions may be carried out according to the methods described herein. The use of one or more compositions may be carried out in the preparation of a therapeutic agent according to the methods described herein. Embodiments are discussed elsewhere throughout this application. Any embodiment discussed with respect to one aspect of this disclosure also applies to other aspects of this disclosure, and vice versa. It will be understood that the embodiments described in the Examples section are embodiments applicable to all aspects of the technology described herein.

[0049] As used herein, the terms "or" and "and / or" are utilized to describe multiple elements in combination or mutually exclusive. For example, "x, y, and / or z" can refer to "x" alone, "y" alone, "z" alone, "x, y, and z," "(x and y) or z," "x or (y and z)," or "x or y or z." It is expressly contemplated that x, y, or z can be specifically excluded from an embodiment.

[0050] Throughout this application, the term "about" is used according to its plain and ordinary meaning within the art of cell biology to indicate that a value includes the standard deviation of error for the device or method being employed to determine the value.

[0051] The term "comprising" is synonymous with "including," "containing," or "characterized by" and is inclusive or open-ended and does not exclude additional unrecited elements or method steps. The phrase "consisting of" excludes any unspecified elements, steps, or ingredients. The phrase "consisting essentially of" limits the scope of the described subject matter to the specified materials or steps and those that do not materially affect its basic and novel characteristics. It is contemplated that embodiments described in the context of the term "comprising" may also be implemented in the context of the term "consisting of" or "consisting essentially of."

[0052] It is expressly contemplated that any of the limitations discussed with respect to one embodiment of the present invention may be applied to any other embodiment of the present invention. Moreover, any of the compositions of the present invention may be used in any of the methods of the present invention, and any of the methods of the present invention may be used to obtain or utilize any of the compositions of the present invention. Aspects of the embodiments shown in the examples are also embodiments that may be implemented in the context of the embodiments discussed elsewhere in different examples or elsewhere in this application (such as the summary of the invention, the detailed description, the claims, and the brief description of the figures).

[0053] The term "therapeutically effective amount" refers to an amount of drug that treats or inhibits a disease or condition. In some embodiments, a therapeutically effective amount inhibits the activity and / or expression of a protein and / or gene described herein by at least, at most, or exactly 100%, 99%, 98%, 96%, 94%, 92%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 40%, 30%, 20%, or 10%, or any range derivable therein. In some embodiments, a therapeutically effective amount increases the activity and / or expression of a protein and / or gene described herein by at least, at most, or exactly 10000%, 1000%, 500%, 200%, 100%, 99%, 98%, 96%, 94%, 92%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 40%, 30%, 20%, or 10%, or any range derivable therein.

[0054] The use of the words "a" or "an" when used in conjunction with the term "comprising" in the claims and / or this specification may mean "one," but is also consistent with the meanings of "one or more," "at least one," and "one or more."

[0055] [The present invention 1001] Formula VII A compound having the chemical structure of TIFF2025000907000018.tif59128, In the formula, R 1 and R 2 is independently H, alkyl, substituted alkyl, aryl, or R 1 and R 2 together form a 4- to 6-membered heterocyclic ring; R 3 and R 4 is independently selected from H, alkyl, substituted alkyl, aryl, or R 3 and R 4 is a bond forming a 5-membered heterocyclic ring, or R 3 and R 4 together form a six-membered heterocyclic ring; R 16 and R 17 is independently selected from H, alkyl, substituted alkyl, aryl, or R 16 and R 17 together form a 4- to 8-membered cycloalkyl or heterocyclic ring; each R 18 is independently alkyl, substituted alkyl, heteroalkyl, cycloalkyl, aryl, or heteroaryl; each R 19 is independently alkyl, substituted alkyl, heteroalkyl, cycloalkyl, aryl, or heteroaryl; h is 0, 1, 2, 3, or 4; k is 1, 2, 3, 4, or 5; Formula VII is a compound of formula VI TIFF2025000907000019.tif49128, not said compound. [The present invention 1002] Formula I The compound of the present invention 1001 has the chemical structure of TIFF2025000907000020.tif63128: In the formula, R 1 and R 2 is independently H, alkyl, substituted alkyl, aryl, or R 1 and R 2 together form a 4- to 6-membered heterocyclic ring; R 3 and R 4is independently selected from H, alkyl, substituted alkyl, aryl, or R 3 and R 4 is a bond forming a 5-membered heterocyclic ring, or R 3 and R 4 together form a six-membered heterocyclic ring; R 5 and R 6 is independently selected from H, alkyl, substituted alkyl, aryl, or R 5 and R 6 is a bond forming a 5-membered heterocyclic ring, or R 5 and R 6 taken together form a 6-membered heterocycle; X is a group having the chemical structure of Formula II, Formula III, Formula IV, or Formula V: TIFF2025000907000021.tif49128In the formula, Z is H, alkyl, substituted alkyl, aryl, OR 7 , or N.R. 8 R 9 ;R 7 is H, alkyl, haloalkyl, substituted alkyl, or aryl; R 8 and R 9 are independently H, alkyl, substituted alkyl, aryl, or R 8 and R 9 together form a 4- to 6-membered heterocycle, J 1 is H, alkyl, or OR 10 Selected from; R 10 is H, alkyl, haloalkyl, substituted alkyl, aryl, or ((CH2) n O) p CH2CH2R 11 (n is 1, 2, or 3; p is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10); R 11 is OH, NH2, or alkoxy; J 2 is H, alkyl, or OR 12 Selected from; R 12 is H, alkyl, haloalkyl, substituted alkyl, aryl, or ((CH2) n O)p CH2CH2R 13 (n is 1, 2, or 3; p is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10); R 13 is OH, NH2, or alkoxy; TIFF2025000907000022.tif25128 where M is O, NH, or CH2; TIFF2025000907000023.tif87128 in formula, R 14 is H or alkoxy, R 15 is H or alkoxy. [The present invention 1003] R 1 is H and R 2 is H and R 3 is H and R 4 is H and R 5 and R 6 The compound of the present invention 1002, wherein is a bond forming a 5-membered heterocycle and X is of formula II. [The present invention 1004] R 1 is H and R 2 is H and R 3 is H and R 4 is H and R 5 and R 6 is a bond forming a 5-membered heterocycle, X is of formula II, Z is H, and J 2 But H and J 1 But, OR 10 The compound of the present invention 1002, [The present invention 1005] R 10 The compound of the present invention 1004, wherein is H, CF3, CH2CH3, CH(CH3)2, CH2CH2CH3, CH2CH2OCH3, CH2CH2OCH2CH2NH2, CH2CH2OCH2CH2OCH2CH2OCH3, CH2NH2, CH2CH2NH2, or CH2CONH2. [The present invention 1006] The compound of the present invention 1001, which is AMBMP analog 1, AMBMP analog 2, AMBMP analog 3, AMBMP analog 4, AMBMP analog 5, AMBMP analog 6, AMBMP analog 8, AMBMP analog 17, AMBMP analog 21, AMBMP analog 25, AMBMP analog 38, AMBMP analog 39, or AMBMP analog 40. [The present invention 1007] A composition comprising any one of the compounds according to the present invention 1001 to 1006, further comprising a pharma- ceutically acceptable carrier. [The present invention 1008] A method for treating muscular dystrophy in a subject, comprising administering to the subject an effective amount of any one of the compounds of the present invention 1001 to 1006 or a pharma- ceutically acceptable salt or solvate thereof. [The present invention 1009] The method of claim 1008, wherein the type of muscular dystrophy is limb-girdle muscular dystrophy. [The present invention 1010] The method of claim 1008, wherein the type of muscular dystrophy is limb-girdle muscular dystrophy type 2A. [The present invention 1011] A method for treating muscle atrophy in a subject, comprising administering to the subject an effective amount of any one of the compounds of the present invention 1001 to 1006 or a pharma- ceutically acceptable salt or solvate thereof. [The present invention 1012] The method of claim 1011, wherein the subject has been determined to have or be at risk for muscle atrophy. [The present invention 1013] The method of any one of claims 1011 to 1012, wherein the subject is being tested for muscle atrophy, or a disease that causes muscle atrophy or a disease associated with muscle atrophy. [The present invention 1014] The method of any of claims 1011 to 1013, wherein the subject has previously been treated with one or more treatments for muscle atrophy. [The present invention 1015] The method of claim 1014, wherein one or more of the treatments for muscle wasting is prescribed chemotherapy. [The present invention 1016] A method for treating cachexia or sarcopenia in a subject, comprising administering to the subject an effective amount of any one of the compounds of the present invention 1001 to 1006 or a pharma- ceutically acceptable salt or solvate thereof. [The present invention 1017] The method of claim 1016, wherein the subject has been diagnosed with cancer. [The present invention 1018] The method of claim 1016 or 1017, wherein the subject is instructed to remain on bed rest. [The present invention 1019] Any of the methods of claims 1016 to 1018, wherein the subject has been diagnosed with age-related sarcopenia. [The present invention 1020] A method for increasing muscle mass in a subject, comprising administering to the subject an effective amount of any one of the compounds of the present invention 1001 to 1006 or a pharma- ceutically acceptable salt or solvate thereof. [The present invention 1021] A method for improving muscle strength in a subject, comprising administering to the subject an effective amount of any one of the compounds of the present invention 1001 to 1006 or a pharma- ceutically acceptable salt or solvate thereof. [The present invention 1022] A method for improving muscle function in a subject, comprising administering to the subject an effective amount of any one of the compounds of the present invention 1001 to 1006 or a pharma- ceutically acceptable salt or solvate thereof. [The present invention 1023] A method for reducing the number of degenerated muscle fibers in a subject, comprising administering to the subject an effective amount of any one of the compounds of the present invention 1001 to 1006 or a pharma- ceutical acceptable salt or solvate thereof. [The present invention 1024] A method for increasing the number of regenerated muscle fibers in a subject, comprising administering to the subject an effective amount of any one of the compounds of the present invention 1001 to 1006 or a pharma- ceutical acceptable salt or solvate thereof. [The present invention 1025] A method for increasing the expression of at least one gene selected from the group consisting of myosin light chain 2, myosin XVIIIb, myomesin 3, lipoprotein lipase, patatin-like phospholipase domain-containing 2, and sarcomeric mitochondrial creatine kinase in a subject, comprising administering to the subject an effective amount of any one of the compounds of the present invention 1001 to 1006 or a pharma-ceutical acceptable salt or solvate thereof. [The present invention 1026] The method according to any one of claims 1008 to 1025, wherein the subject has a mutation in calpain 3 gene. [The present invention 1027] The method of any of claims 1008 to 1026, wherein the subject has been determined to have a deficiency in CaMKII. [The present invention 1028] The method of any one of claims 1008 to 1027, further comprising determining the expression level or activity level of CaMKII. [The present invention 1029] The method according to any one of claims 1008 to 1028, wherein said compound is administered orally, parenterally, subcutaneously, intraperitoneally, or intramuscularly. [The present invention 1030] The method of any one of claims 1008 to 1029, wherein the compound is administered topically. [The present invention 1031] The method of claim 1030, wherein said compound is administered to muscle tissue. [The present invention 1032] The method according to any one of claims 1008 to 1031, wherein the subject is a human. Other objects, features, and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and specific examples, while indicating preferred embodiments of the present invention, are given by way of example only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description. [Brief description of the drawings]

[0056] The following drawings form part of the present specification and are included to further demonstrate certain aspects of the invention. An understanding of the invention can be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.

[0057] [Figure 1A] AMBMP analog 1 is shown. [Figure 1B] AMBMP analog 2 is shown. [Figure 1C] AMBMP analog 3 is shown. [Figure 1D] AMBMP analog 4 is shown. [Figure 1E] AMBMP analog 5 is shown. [Figure 1F] AMBMP analog 6 is shown. [Figure 1G] AMBMP analog 7 is shown. [Figure 1H] AMBMP analog 8 is shown. [Figure 1I] AMBMP analog 9 is shown. [Figure 1J] AMBMP analog 10 is shown. [Figure 1K] AMBMP analog 11 is shown. [Figure 1L] AMBMP analog 12 is shown. [Figure 1M] AMBMP analog 13 is shown. [Figure 1N] AMBMP analog 14 is shown. [Figure 1O] AMBMP analog 15 is shown. [Figure 1P]AMBMP analog 16 is shown. [Figure 1Q] AMBMP analog 17 is shown. [Figure 1R] AMBMP analog 18 is shown. [Figure 1S] AMBMP analog 19 is shown. [Figure 1T] AMBMP analog 20 is shown. [Figure 1U] AMBMP analog 21 is shown. [Figure 1V] AMBMP analog 39 is shown. [Figure 1W] AMBMP analog 40 is shown. [Figure 1X] AMBMP analog 41 is shown. [Figure 1Y] AMBMP analog 42 is shown. [Figure 1Z] AMBMP analog 43 is shown. [Figure 1AA] AMBMP analog 44 is shown. [Figure 1BB] AMBMP analog 45 is shown. [Figure 2A] AMBMP analog 22 (M=O) is shown. [Figure 2B] AMBMP analog 23 (M=NH) is shown. [Figure 2C] AMBMP analog 24 (M=CH2) is shown. [Diagram 3] AMBMP analog 25 is shown. [Figure 4A] AMBMP analog 26 is shown. [Figure 4B] AMBMP analog 27 is shown. [Figure 4C] AMBMP analog 28 is shown. [Figure 4D] AMBMP analog 29 is shown. [Figure 4E] AMBMP analog 30 is shown. [Figure 4F] AMBMP analog 31 is shown. [Figure 4G] AMBMP analog 32 is shown. [Figure 5A] AMBMP analog 33 is shown. [Figure 5B] AMBMP analog 34 is shown. [Figure 6A] AMBMP analog 35 is shown. [Figure 6B] AMBMP analog 36 is shown. [Figure 7A] AMBMP analog 37 is shown. [Figure 7B] AMBMP analog 38 is shown. [Figure 8] 1 shows signaling pathways induced by exercise and activation of gene transcription. [Figure 9] In limb-girdle muscular dystrophy type 2A, CAPN3 is mutated, which reduces CAMK signaling and blunts downstream gene transcription. [Figure 10] In calpain 3-deficient muscles, we show that once atrophy has developed, myofibrillar genes are not properly induced after exercise or during muscle loading. [Figure 11] We show that slow muscle fiber diameter is increased in C3KO mice treated with AMBMP. [Figure 12] We show that mitochondrial oxidative function is improved in a dose-dependent manner in C3KO mice treated with AMBMP. [Figure 13] 1 shows that AMBMP treatment improves exercise capacity. [Figure 14] We show that AMBMP treatment increases CaMKIIβ activity, while neither AMPK nor AKT signaling is affected. [Figure 15] We show that AMBMP increases oxidative slow-twitch muscle fibers in calpainopathy mice. [Figure 16A] Relative expression of myosin light chain 2 (Myl2) gene following treatment with 0.0 μM, 1.25 μM, 2.5 μM, and 5 μM of AMBMP analogs 1 to 6, AMBMP analog 17, AMBMP analog 18, and AMBMP analog 25 is shown. [Figure 16B]Activation of CaMKIIβ in mouse skeletal muscle harvested after injection of AMBMP analog 3 at 10 mg / kg was demonstrated by assessing phosphorylated CaMKIIβ (P-CaMKII or P-CaMK) activity by Western blot using an anti-phosphorylated CaMKIIβ antibody. [Figure 16C] P-CaMK was assessed in mice injected intraperitoneally with AMBMP analog 3 at 10 mg / kg, normalized by gel loading amount. [Figure 16D] 2 shows the expression of Myl2 in the plantaris muscle assessed by RT-PCR in mice intraperitoneally injected with 10 mg / kg AMBMP analog 3. Myl2 expression was normalized to GAPDH as a housekeeping control gene. [Figure 16E] Expression of Myl2 normalized to GAPDH is shown for C2C12 myogenic cells treated with AMBMP (at concentrations of 1.25 μM, 2.5 μM) and AMBMP analog 40 (1.25 μM, 5 μM) for 48 hours. [Figure 17A] 1 shows a synthetic scheme for AMBMP analogs. Scheme I. [Figure 17B] 1 shows a synthetic scheme for AMBMP analogs. Scheme II. [Figure 17C] 1 shows a synthetic scheme for AMBMP analogs. Scheme III. [Figure 17D] 4 shows a synthetic scheme for AMBMP analogs. Scheme IV. [Figure 18A] AMBMP analog 46 is shown. [Figure 18B] AMBMP analog 47 is shown. [Figure 18C] AMBMP analog 48 is shown. [Figure 18D] AMBMP analog 49 is shown. [Figure 18E] AMBMP analog 50 is shown. [Figure 19A] AMBMP analog 51 is shown. [Figure 19B] AMBMP analog 52 is shown. [Figure 19C]AMBMP analog 53 is shown. [Figure 19D] AMBMP analog 54 is shown. [Figure 19E] AMBMP analog 55 is shown. [Figure 19F] AMBMP analog 56 is shown. [Figure 19G] AMBMP analog 57 is shown. [Figure 19H] AMBMP analog 58 is shown. [Figure 19I] AMBMP analog 59 is shown. [Figure 19J] AMBMP analog 60 is shown. [Figure 19K] AMBMP analog 61 is shown. [Figure 19L] AMBMP analog 62 is shown. [Figure 19M] AMBMP analog 63 is shown. [Figure 19N] AMBMP analog 64 is shown. [Figure 19O] AMBMP analog 65 is shown. [Figure 19P] AMBMP analog 66 is shown. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0058] Description of Example Embodiments I. Compound It has been identified that compounds having the chemical structure of formula I and / or formula VII, or pharma- ceutical acceptable salts or solvates thereof, can increase muscle mass and improve muscle function. Such chemicals can be effective in treating muscular dystrophies, such as limb-girdle muscular dystrophy type 2A / R1 / D1. Without being bound by theory, it is believed that such compounds can exert their biological effects by reversing the blockade of CAMKII signaling by activating CaMKII. Thus, they can increase muscle size, mitochondrial complex I and mitochondrial complex II activity, expression of genes that constitute slow-twitch fiber phenotype and athletic performance. Embodiments of the present disclosure are directed to compositions and methods of use of compounds having the chemical structure of formula I and / or formula VII, or pharma-ceutical acceptable salts or solvates thereof, which exhibit activity against CAMKII signaling equal to or greater than that of AMBMP, but are less toxic and / or more soluble than AMBMP (formula VI). One or more of the compounds having the chemical structure of Formula I may have a lower logP value compared to the logP value of AMBMP, and the logP value difference may be at least any one of, equal to, or between any two of 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, and 1.8, where P is the partition coefficient of the compound between the organic phase and the aqueous phase (i.e., P=[organic phase] / [aqueous phase]). One or more of the compounds having the chemical structure of Formula I and / or Formula VII may have an EC50 potency for the endogenous myosin light chain 2 (Myl2) promoter in C2C12 cells of less than 1 uM. The solubility of the compound in water at standard temperature and pressure may be greater than 10 uM. Less than 98.5% of the compound may bind to human albumin. The stability of the compound in human serum at 37° C. and standard pressure may be greater than 10 uM. 1 / 2The stability may be greater than 0.5 hours. The stability may include stability from degradation and / or metabolism. The compound may be orally bioavailable. Orally bioavailable may include a 50% molar rate at which the compound enters the human bloodstream after oral administration. The compound may have a cytotoxicity of greater than 50 μM, resulting in 50% cell death. Toxicity may be measured as a dose-dependent effect of the compound on cell death of C2C12 cells.

[0059] Certain embodiments are set forth in the claims. In some embodiments, a method of treating muscular dystrophy in a subject is provided, the method comprising administering to the subject an effective amount of a compound having the chemical structure of Formula I and / or Formula VII, or a pharma- ceutically acceptable salt or solvate thereof.

[0060] Other methods include increasing muscle mass in a subject, improving muscle strength in a subject, improving muscle function in a subject, reducing the number of degenerated muscle fibers in a subject, increasing the number of regenerated muscle fibers in a subject, and increasing the expression of at least one gene selected from the group consisting of myosin light chain 2, myosin XVIIIb, myomesin 3, lipoprotein lipase, patatin-like phospholipase domain-containing 2, and sarcomeric mitochondrial creatine kinase in a subject. Such methods may include administering to a subject an effective amount of a compound having the chemical structure of Formula I and / or Formula VII, or a pharma- ceutical acceptable salt or solvate thereof.

[0061] In some embodiments, a composition is administered to a subject, and the active ingredient in the composition is a compound described herein.

[0062] In some embodiments, the type of muscular dystrophy treated in the subject is limb-girdle muscular dystrophy. In certain embodiments, the type of muscular dystrophy is limb-girdle muscular dystrophy type 2A / R1 / D1. In some embodiments, the route of administration to the subject is oral, parenteral, subcutaneous, intraperitoneal, or intramuscular. In additional embodiments, the compound is administered topically. In another embodiment, the compound is administered directly to muscle tissue. In additional embodiments, the compound is given to the subject in multiple doses. In some cases, the compound is formulated into a composition that includes pharma- ceutical acceptable excipients.

[0063] In some embodiments, the muscle mass of the subject is increased compared to the muscle mass before administration of the compound having the chemical structure of Formula I and / or Formula VII, or a pharma- ceutical acceptable salt or solvate thereof. In certain embodiments, the muscle strength of the subject is increased compared to the muscle strength before administration of the compound having the chemical structure of Formula I and / or Formula VII, or a pharma- ceutical acceptable salt or solvate thereof. The method may also improve the muscle function of the subject compared to the muscle function before treatment. In other cases, the number of degenerated muscle fibers in the subject is decreased compared to the number of degenerated muscle fibers in the subject before treatment, or the number of regenerated muscle fibers in the subject is increased compared to the number of regenerated muscle fibers in the subject before treatment. In certain embodiments, the expression of at least one gene selected from the group consisting of myosin light chain 2, myosin XVIIIb, myomesin 3, lipoprotein lipase, patatin-like phospholipase domain-containing 2, and sarcomeric mitochondrial creatine kinase is increased compared to the expression of the gene before treatment. In some cases, the subject has a mutation in the calpain 3 gene. In other cases, the mutation is detected before treatment. In some embodiments, the subject may be a mammal, and in other embodiments, it is contemplated that the subject is a human.

[0064] In some cases, the subject has been determined to have muscle atrophy or to be at risk for muscle atrophy. In other embodiments of the method, the subject is examined for muscle atrophy or a disease that causes or is associated with muscle atrophy. In certain embodiments, the subject has previously been treated with one or more treatments for muscle atrophy, such as prescribed chemotherapy (e.g., prescription drugs). In some embodiments, the subject has not been treated for gastrointestinal disease or gastrointestinal condition with lansoprazole or rabeprazole. In certain methods, the subject does not suffer from any symptoms of gastrointestinal disease or gastrointestinal condition at the time lansoprazole or rabeprazole is administered.

[0065] Methods and compositions are provided for the treatment of muscle atrophy, myopathy, or muscular dystrophies, which are a category of diseases and conditions that involve progressive weakness and degeneration of skeletal muscles that control movement. The embodiments may be applied to the following types of muscular dystrophies: myotonic muscular dystrophy, facioscapulohumeral muscular dystrophy (FSHD), congenital muscular dystrophy, or limb-girdle muscular dystrophy. In some embodiments, the disease or condition that may be treated is caused by or associated with a decrease in activity and / or expression of calpain 3 or Ca-calmodulin-dependent protein kinase II (CaMKII), or both. In certain embodiments, the disease is limb-girdle muscular dystrophy type 2A / R1 / D1 (LGMD2A / R1 / D1). In additional embodiments, the disease or condition may be any of the following: disuse atrophy, acid maltase deficiency (AMD), amyotrophic lateral sclerosis (ALS), Andersen-Tawil syndrome, Becker muscular dystrophy (BMD), Becker congenital myotonia, Bethlem myopathy, Bulbospinal Muscular Atrophy (Spinal-Bulbar Muscular Atrophy), and / or vascular endothelial cell carcinoma (VECC). Atrophy), carnitine deficiency, carnitine palmityltransferase deficiency (CPT deficiency), central core disease (CCD), centronuclear myopathy, Charcot-Marie-Tooth disease (CMT), congenital muscular dystrophy (CMD), congenital myasthenic syndrome (CMS), congenital myotonic dystrophy, Cori disease (debranching enzyme deficiency), debranching enzyme deficiency, Dejerine-Sottas disease (DSD), dermatomyositis (DM), distal muscular dystrophy (DD), Duchenne muscular dystrophy DMD, myotonic dystrophy (myotonic dystrophy), Emery-Dreifuss muscular dystrophy (EDMD), endocrine myopathy, Eulenberg disease (congenital paramyotonia), facioscapulohumeral muscular dystrophy (FSH or FSHD), Finnish (tibialis anterior) distal myopathy, Forbes disease (debranching enzyme deficiency), Friedreich's ataxia (FA), Fukuyama congenital muscular dystrophy, glycogen storage disease type 10, glycogen storage disease type 11, glycogen storage disease type 2, glycogen storage disease type 3, glycogen storage disease type 5,Glycogen storage disease type 7, Glycogen storage disease type 9, Gowers-Laing distal myopathy, Hauptmann-Thanheuser MD (Emery-Dreifuss muscular dystrophy), Hereditary inclusion body myositis, Hereditary motor and sensory neuropathy (Charcot-Marie-Tooth disease), Hyperthyroid myopathy, Hypothyroid myopathy, Inclusion body myositis (IBM), Hereditary myopathy, Integrin deficiency congenital muscular dystrophy, Kennedy disease (spinal-bulbar muscular atrophy), Kugelberg-Welander disease (spinal muscular atrophy), Lactate dehydrogenase deficiency, Lambert-Eaton myasthenic syndrome (LEMS) ), limb-girdle muscular dystrophy (LGMD), Lou Gehrig's disease (amyotrophic lateral sclerosis), McArdle disease (phosphorylase deficiency), merosin-deficient congenital muscular dystrophy, muscle metabolic disease, mitochondrial myopathy, Miyoshi-type distal myopathy, motor neuron disease, muscle-eye-brain disease, myasthenia gravis (MG), myoadenylate deaminase deficiency, myofibrillar myopathy, muscle phosphorylase deficiency, myotonia congenital (MC), myotonic muscular dystrophy (MMD), myofibrillar myopathy Myopathy (MTM or MM), nemaline myopathy, intermediate distal myopathy, oculopharyngeal muscular dystrophy (OPMD), congenital paramyotonia, Pearson syndrome, periodic paralysis, peroneal muscular atrophy (Charcot-Marie-Tooth disease), phosphofructokinase deficiency, phosphoglycerate kinase deficiency, phosphoglycerate mutase deficiency, phosphorylase deficiency, phosphorylase deficiency, polymyositis (PM), Pompe disease (acid maltase deficiency), progressive exocrine glandular dystrophy (EGD), Ophthalmoplegia (PEO), rod disease (nemaline myopathy), spinal muscular atrophy (SMA), spinal-bulbar muscular atrophy (SBMA), Steinert disease (myotonic muscular dystrophy), Tarui disease (phosphofructokinase deficiency), Thomsen disease (congenital myotonia), Ullrich congenital muscular dystrophy, Walker-Warburg syndrome (congenital muscular dystrophy), Welander distal myopathy, Werdnig-Hoffmann disease (spinal muscular atrophy), or ZASP-associated myopathy. Such diseases or conditions are characterized by reduced muscle mass, muscle weakness, decreased muscle function, increased degenerated muscle fibers, decreased regenerated muscle fibers, and decreased expression of myosin light chain 2, myosin XVIIIb, myomesin 3, or β-amyloides in the subject.decreased expression of one or more genes selected from the group consisting of lipoprotein lipase, patatin-like phospholipase domain-containing 2, and sarcomeric mitochondrial creatine kinase.

[0066] Limb-girdle muscular dystrophy type 2A / R1 / D1 (LGMD2A / R1 / D1) is caused by mutations in the non-lysosomal cysteine ​​protease calpain 3 (CAPN3). Muscles from patients and mice lacking CAPN3 or from patients with CAPN3 mutations have greatly reduced muscle mass, but unlike dystrophinopathies, their sarcolemma is stable, suggesting that the pathogenesis of LGMD2A / R1 / D1 is distinct from that of dystrophinopathies. CAPN3 localizes to several intracellular compartments, including the triad, where it is activated by calmodulin and plays an undetermined role in calcium release. Previous studies from our laboratory have shown that muscles from Capn3 knockout (C3KO) mice fail to grow after atrophy development. This is accompanied by impaired Ca calmodulin-dependent protein kinase II (CaMKII) signaling. While the expression of several slow-twitch genes (e.g., Myl2, Mybph, and Ckmt2) is increased in muscles of WT mice subjected to exercise training, these adaptive changes to exercise do not occur in muscles of C3KO mice. Similarly, myofibrillar, cytoskeletal, mitochondrial, and lipid metabolism genes are also slowed in C3KO mice. Consistent with our mouse studies, we observed preferential involvement of slow-twitch fibers in pathology in LGMD2A biopsies. Thus, enhancing the expression of CaMKII-induced genes represents a novel target for LGMD2A / R1 / D1. Compounds that activate these slow-twitch genes may have therapeutic potential for LGMD2A / R1 / D1. To identify such compounds, we designed a high-throughput screen using C2C12 cells with a stable Myl2 promoter reporter. The reporter expression reflects the expression pattern of endogenous Myl2 that occurs during C2C12 differentiation. Using these cells, we performed a high-throughput screen to identify drugs that reverse the blockade of CAMKII signaling to treat LGMD2A / R1 / D1, and positive hits were validated in a secondary screen.These positive hits will be tested in mouse models, which will serve as the primary high-throughput screening approach to identify drugs against LGMD2A / R1 / D1.

[0067] In certain embodiments, the method comprises administering an effective amount of at least one first compound and an effective amount of at least one second compound, wherein the first compound is a compound having the chemical structure of Formula I and / or Formula VII or a pharma- ceutically acceptable salt or solvate thereof, and the second compound is selected from the group consisting of 6-methyl-2-(phenylethynyl)pyridine hydrochloride, (2'Z,3'E)-6-bromoindirubin-3'-oxime, daidzein, lansoprazole, nabumetone, parbendazole, PD-98059, phenamyl methanesulfonate, phenazopyridine, rabeprazole, rutaecarpine, SB-204741, SB-206553 hydrochloride hydrate, SB-366791, and SIB1893. In some aspects, the first compound is a compound depicted in Figures 1-7, 18, or 19, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty-one, thirty-one, thirty-two, thirty-three, thirty-four, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66 or more (or any range derivable therein) may be excluded. In some embodiments, one or more of the second compounds may be excluded. The first compound and the second compound may be administered simultaneously or separately. Compositions and methods of use of the second compounds are discussed in PCT application WO2017 / 208211 by Spencer et.al., the disclosure of which is incorporated herein by reference.

[0068] Certain embodiments are directed to pharmaceutical compositions comprising an effective amount of at least one first compound and an effective amount of at least one second compound, wherein the first compound is a compound having the chemical structure of Formula I and / or Formula VII or a pharma- ceutically acceptable salt or solvate thereof, and the second compound is selected from the group consisting of 6-methyl-2-(phenylethynyl)pyridine hydrochloride, (2'Z,3'E)-6-bromoindirubin-3'-oxime, daidzein, lansoprazole, nabumetone, parbendazole, PD-98059, phenamyl methanesulfonate, phenazopyridine, rabeprazole, rutaecarpine, SB-204741, SB-206553 hydrochloride hydrate, SB-366791, and SIB1893. In some aspects, the first compound is a compound depicted in Figures 1-7, 18, or 19, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty-one, thirty-one, thirty-two, thirty-three, thirty-four, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, or more (or any range derivable therein) may be excluded. In some embodiments, one or more of the second compounds may be excluded. In some embodiments, the pharmaceutical composition may include a pharma- ceutically acceptable carrier. In some embodiments, the pharmaceutical composition may include a pharma- ceutical excipient.

[0069] Analysis of gene expression A gene will be understood to be specifically expressed in a particular cell type if the expression level of that gene in that cell type is at least 2-fold, at least 5-fold, at least 10-fold, at least 100-fold, at least 1000-fold, or at least 10000-fold higher than in a reference cell type or mixture of reference cell types. Reference cell types include non-diseased tissue cells or heterogeneous populations of diseased tissue cells.

[0070] In certain embodiments, the expression level determination is performed on a gene chip (such as an Affymetrix™ gene chip). In some embodiments, the expression level determination is performed by RNA sequencing. In other embodiments, the expression level determination is performed by kinetic real-time PCR.

[0071] Expression patterns can also be compared by using one or more ratios between the expression levels of different biomarkers. Other suitable measures or indices can also be used to assess the association or difference between different expression patterns.

[0072] The expression level of a biomarker can be compared to a reference expression level using various methods. Such a reference level can be determined using the expression level of a reference based on all patients. Alternatively, the expression level can be based on an internal reference (such as a gene expressed in all cells). In some embodiments, the reference is a gene that is expressed in diseased cells at a higher level compared to that of any of the biomarkers. Any comparison can be performed using the fold change or absolute difference between the expression levels being compared. Such a comparison can use one or more biomarkers. It is contemplated that one, two, three, four, five, six, seven, eight, nine, ten, and / or eleven biomarkers (or any range derivable therefrom) can be used for comparison with each other and / or with an internal or external reference. A person skilled in the art would know how to perform such a comparison.

[0073] The fold increase or decrease can be at least or at most 1 fold, 2 fold, 3 fold, 4 fold, 5 fold, 6 fold, 7 fold, 8 fold, 9 fold, 10 fold, 11 fold, 12 fold, 13 fold, 14 fold, 15 fold, 16 fold, 17 fold, 18 fold, 19 fold, 20 fold, 25 fold, 30 fold, 35 fold, 40 fold, 45 fold, 50 fold, 55 fold, 60 fold, 65 fold, 70 fold, 75 fold, 80 fold, 85 fold, 90 fold, 95 fold, 100 fold, or more, or any range derivable therein. Alternatively, the difference in expression can be expressed as a percentage decrease or increase, where such a percentage decrease or increase is at least or at most 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, 1000%, or any range derivable therein.

[0074] Another way to express relative expression levels is using normalized or relative numbers, such numbers being 0.001, 0.002, 0.003, 0.004, 0.005, 0.006, 0.007, 0.008, 0.009, 0.01, 0.02, 0.03. 0.04, 0.05, 0.06, 0.07, 0.08, 0.0 9, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5 ,3.6,3.7,3.8,3.9,4.0,4.1,4.2,4.3,4.4,4.5,4.6,4.7,4.8,4.9,5.0,5.1,5.2,5.3,5.4,5.5,5.6,5.7,5.8,5.9,6.0,6.1,6.2,6.3,6.4,6.5,6.6,6.7,6.8,6.9,7.0 , 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10.0, or any range derivable therein. In some embodiments, the levels can be relative to a non-metastatic control or relative to a metastatic control.

[0075] Algorithms (such as weighted voting programs) may be used to facilitate the assessment of biomarker levels. Additionally, other clinical evidence may be combined with biomarker-based testing to reduce the risk of false positives. In some embodiments, other cytogenetic assessments may be considered.

[0076] Any diseased cell-containing biological sample from a patient can be used to evaluate the expression pattern of any of the biomarkers discussed herein.In some embodiments, a biological sample from muscle is used.The evaluation of the sample may, but does not necessarily, involve panning (enrichment) of muscle cells or isolating muscle cells.

[0077] Measuring Gene Expression Using Nucleic Acids Test methods based on differential expression of gene products are well known in the art.In one embodiment, the differential expression pattern of biomarkers can be determined by measuring the RNA transcript levels of these genes or the RNA transcript levels of genes whose expression is regulated by these genes in patient cells.Methods suitable for this purpose include, but are not limited to, RT-PCR, Northern blot, in situ hybridization, Southern blot, slot blot, nuclease protection assay, and oligonucleotide array.

[0078] In certain aspects, RNA isolated from cells can be amplified and converted to cDNA or cRNA before detection and / or quantification. The isolated RNA can be either total RNA or mRNA. RNA amplification can be specific or non-specific. Suitable amplification methods include, but are not limited to, reverse transcriptase PCR, isothermal amplification, ligase chain reaction, and Q-beta replicase. Amplified nucleic acid products can be detected and / or quantified by hybridization to a labeled probe. In some embodiments, detection can use fluorescence resonance energy transfer (FRET) or some other type of quantum dot.

[0079] Amplification primers or hybridization probes for the biomarkers can be prepared from the gene sequence or obtained through commercial sources (such as Affymatrix). In certain embodiments, the gene sequence is identical to or complementary to at least 8 consecutive nucleotides of the coding sequence.

[0080] Suitable sequences for preparing probes / primers for detecting the corresponding biomarkers include sequences identical to or complementary to all or a portion of the biomarker genes described herein (such as CaMKII, myosin light chain 2, myosin XVIIIb, myomesin 3, lipoprotein lipase, patatin-like phospholipase domain-containing 2, and sarcomeric mitochondrial creatine kinase).

[0081] Stable and selective double-stranded molecules can be formed using probes or primers with lengths of 13-100 nucleotides, specifically 17-100 nucleotides, or in some embodiments up to 1-2 kilobases or more. Molecules with complementary sequences spanning a continuous stretch of more than 20 bases in length can improve the stability and / or selectivity of the resulting hybrid molecules. Nucleic acid molecules with one or more complementary sequences of 20-30 nucleotides, or even longer if desired, can be designed for hybridization. Such fragments can be readily prepared, for example by directly synthesizing them by chemical means or by introducing selected sequences into a recombinant vector for recombinant production.

[0082] In one embodiment, each probe / primer contains at least 15 nucleotides. For example, each probe may contain at least or at most 20, 25, 50, 75, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 400, or more nucleotides (or any range derivable therein). Such probes / primers may have such lengths and may have sequences identical or complementary to the genes described herein. Specifically, each probe / primer has a relatively high sequence complexity and does not have any ambiguous residues (undetermined "n" residues). The probes / primers may hybridize to the target gene (including its RNA transcript) under stringent or highly stringent conditions. In some embodiments, since there are multiple human sequences for each of the biomarkers, it is contemplated that probes and primers may be designed for use with each of these sequences. For example, inosine is a nucleotide that is frequently used in probes or primers for hybridization to multiple sequences. It is contemplated that a probe or primer may have inosine or other design implementations that allow recognition of multiple human sequences of a particular biomarker.

[0083] For applications requiring high selectivity, it is typically desirable to form hybrids using relatively stringent conditions. For example, relatively low salt concentration and / or relatively high temperature conditions (such as those obtained by setting the NaCl concentration to about 0.02M to about 0.10M and the temperature to about 50°C to about 70°C). Under such highly stringent conditions, mismatches between the probe or primer and the template strand or target strand are hardly tolerated, even if they occur, and such highly stringent conditions are considered to be particularly suitable for isolating a specific gene or detecting a specific mRNA transcript. It will be understood that the stringency of the conditions can generally be increased by increasing the amount of formamide added.

[0084] In another embodiment, the probe / primer for a gene is selected from a region that is significantly different from the sequence of other genes. Such a region can be determined by searching the probe / primer sequence against a human genome sequence database (such as NCBI's Entrez database). One suitable algorithm for this purpose is the BLAST algorithm. This algorithm involves first identifying high-scoring sequence pairs (HSPs) by identifying short strings of length W in a query sequence that match or meet some positive threshold score T when aligned with a string of the same length in a database sequence. T is referred to as the contiguous string score threshold. These initial contiguous string hits act as seeds to initiate a search to find longer HSPs that contain them. The string hits are then extended in both directions along each sequence to increase the cumulative alignment score. The cumulative score is calculated using the parameters M (reward score for a matched residue pair (always >0)) and N (penalty score for mismatched residues (always <0)) for nucleotide sequences. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment, and those skilled in the art understand that such parameters can be adjusted to suit different purposes.

[0085] In one embodiment, quantitative RT-PCR (such as TaqMan (ABI)) is used to detect and compare the levels of RNA transcripts in samples. In quantitative RT-PCR, reverse transcription (RT) of RNA into cDNA is performed, followed by relative quantitative PCR (RT-PCR). The concentration of target DNA in the linear portion of the PCR process is proportional to the starting target concentration before PCR begins. By determining the concentration of PCR products of target DNA in PCR reactions that have completed the same number of cycles, where such PCR reactions are in their linear range, it is possible to determine the relative concentration of a specific target sequence in the initial DNA mixture. If the DNA mixture is cDNA synthesized from RNA isolated from different tissues or cells, the relative abundance of the specific mRNA from which the target sequence is derived can be determined for each tissue or cell. In the linear range portion of the PCR reaction, this direct proportionality holds between PCR product concentration and relative mRNA abundance. The final concentration of target DNA in the plateau portion of the curve is determined by the availability of reagents in the reaction mixture and is independent of the initial target DNA concentration. Therefore, sampling and quantification of amplified PCR products can be performed when the PCR reaction is in the linear portion of the curve.Furthermore, the relative concentration of amplifiable cDNA can be normalized with some independent standard, which can be based on internally present RNA species or on exogenously introduced RNA species.The abundance of a particular mRNA species can also be determined relative to the average abundance of all mRNA species in the sample.

[0086] In one embodiment, one or more internal PCR standards are utilized in PCR amplification.Internal standards can be housekeeping genes that are abundant in cells, or can be specifically GAPDH, GUSB, and β-2 microglobulin.These standards can be used to normalize expression levels, so that the expression levels of different gene products can be directly compared.Those skilled in the art will know how to use internal standards to normalize expression levels.

[0087] An inherent problem with clinical samples is the variability in the content and / or quality of such samples. This problem can be overcome if RT-PCR is performed as relative quantitative RT-PCR with an internal standard, where the internal standard is an amplifiable cDNA fragment of equal or greater size than the target cDNA fragment, and the abundance of the mRNA encoding the internal standard is approximately 5-100 times greater than the mRNA encoding the target. This assay measures the relative abundance of each mRNA species, rather than the absolute abundance.

[0088] In another embodiment, an external standard protocol is used in relative quantitative RT-PCR. Under this protocol, PCR products are sampled in the linear part of their amplification curve. The optimal PCR cycle number for sampling can be empirically determined for each target cDNA fragment. Furthermore, the reverse transcriptase products of each RNA population isolated from various samples can be normalized to ensure equal concentrations of amplifiable cDNA.

[0089] Nucleic acid arrays can also be used to detect and compare the expression pattern differences of biomarkers in cells. Probes suitable for detecting corresponding biomarkers can be stably attached to known distinct regions on a solid-phase substrate. As used herein, a probe is "stably attached" to a distinct region if it maintains its position relative to the distinct region during hybridization and subsequent washing. The construction of nucleic acid arrays is well known in the art. Substrates suitable for preparing polynucleotide arrays include, but are not limited to, membranes, films, plastics, and quartz wafers.

[0090] The nucleic acid array may contain at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, or more different polynucleotide probes that may hybridize to different and / or the same biomarkers. Multiple probes for the same gene may be used on a single nucleic acid array. The nucleic acid array may also include probes for other disease genes. The probe density on the array may be within any range. In some embodiments, the density (number of probes / cm 2 ) may be 50, 100, 200, 300, 400, 500, or more.

[0091] Chip-based nucleic acid technologies, such as those described by Hacia et al. (1996) and Shoemaker et al. (1996), are specifically contemplated. Briefly, these techniques provide a quantitative method for rapid and accurate analysis of many genes. By tagging genes with oligonucleotides or using fixed probe arrays, chip technology can be used to isolate and screen target molecules in high density arrays on a hybridization basis (see also Pease et al., 1994 and Fodor et al, 1991). For diagnostic, prognostic and therapeutic methods, it is contemplated that this technology may be combined with the assessment of expression levels of one or more biomarkers.

[0092] Certain embodiments may include using arrays or using data obtained from arrays. The data may be readily available. Furthermore, arrays may be prepared such that after the data is obtained, it can be used in relevant studies.

[0093] Arrays generally refer to ordered macroarrays or microarrays of nucleic acid molecules (probes) that are fully or nearly complementary or identical to multiple mRNA or cDNA molecules and arranged on a carrier material in a spatially separated configuration. Macroarrays are typically nitrocellulose or nylon sheets onto which the probes are spotted. Microarrays have a more dense arrangement of nucleic acid probes, so that up to 10,000 nucleic acid molecules can fit in an area (typically 1-4 square centimeters). Microarrays can be made by spotting nucleic acid molecules (e.g., genes, oligonucleotides, etc.) onto a substrate or by assembling oligonucleotide sequences in situ on a substrate. The spotted or assembled nucleic acid molecules can be applied in a high density matrix pattern with up to about 30 or even more non-identical nucleic acid molecules per square centimeter (e.g., up to about 100 or even 1000 per square centimeter). In contrast to the nitrocellulose-based materials used in filter arrays, microarrays typically use coated glass as the solid support. By perfectly matching the arrangement of the ordered array with the nucleic acid sample, the position of each sample can be tracked and linked to the original sample. A variety of different array devices are known to those skilled in the art, in which a plurality of different nucleic acid probes are stably attached to the surface of a solid support. Substrates useful for arrays include nylon, glass, and silicon. Such arrays can differ in many different ways, including the average probe length, the sequence or type of the probe, the nature of the bond (e.g., covalent or non-covalent) between the probe and the array surface, and the like. The labeling and screening methods and arrays are not limited in their utility with respect to any parameter, except that the probe is one that detects expression levels, and as a result, the methods and compositions can be used for a variety of different types of genes.

[0094] Representative methods and apparatus for preparing microarrays are described in, e.g., U.S. Patent Nos. 5,143,854, 5,202,231, 5,242,974, 5,288,644, 5,324,633, 5,384,261, 5,405,783, 5,412,087, 5,424,186, 5,429,807, 5,432,049, 5,436,327, 5,445,934, 5,452,102, and 5,453,102. No. 5,468,613, No. 5,470,710, No. 5,472,672, No. 5,492,806, No. 5,525,464, No. 5,503,980, No. 5,510,270, No. 5,525,464, No. 5 ,527,681, 5,529,756, 5,532,128, 5,545,531, 5,547,839, 5,554,501, 5,556,752, 5,561,071, 5, 571,639, 5,580,726, 5,580,732, 5,593,839, 5,599,695, 5,599,672, 5,610,287, 5,624,711, 5,6 No. 31,134, No. 5,639,603, No. 5,654,413, No. 5,658,734, No. 5,661,028, No. 5,665,547, No. 5,667,972, No. 5,695,940, No. 5,70 No. 0,637, No. 5,744,305, No. 5,800,992, No. 5,807,522, No. 5,830,645, No. 5,837,196, No. 5,871,928, No. 5,847,219, No. 5,876 ,932, 5,919,626, 6,004,755, 6,087,102, 6,368,799, 6,383,749, 6,617,112, 6,638,717, 6,720,138, as well as WO93 / 17126, WO95 / 11995, WO95 / 21265, WO95 / 21944, WO95 / 35505, WO96 / 31622, WO97 / 10365, WO97 / 27317, WO99 / 35505, WO09923256, WO09936760, WO0138580, WO0168255, WO0302089 8, WO03040410, WO03053586, WO03087297, WO03091426, WO03100012, WO04020085, WO04027093, EP373203, EP785280, EP799897, and UK8803000, the disclosures of which are all incorporated herein by reference.

[0095] It is contemplated that the array may be a high density array, such that the number of different probes contained in such an array is 100 or more. It is contemplated that the number of different probes contained in such an array may be 1000, 16,000, 65,000, 250,000, or 1,000,000 or more. The probes may be directed to targets in one or more different organisms. In some embodiments, the length of the oligonucleotide probe ranges from 5 to 50, 5 to 45, 10 to 40, or 15 to 40 nucleotides. In certain embodiments, the length of the oligonucleotide probe ranges from 20 to 25 nucleotides.

[0096] The location and sequence of each different probe sequence in the array is generally known. Furthermore, the large number of different probes occupy a relatively small area, thereby increasing the probe density (cm 2 The number of different oligonucleotide probes per array (number of different oligonucleotide probes per array) can generally be greater than about 60, greater than about 100, greater than about 600, greater than about 1000, greater than about 5,000, greater than about 10,000, greater than about 40,000, greater than about 100,000, or greater than about 400,000. The surface area of ​​the array is about 1 cm 2 , approx. 1.6cm 2 , about 2 cm 2 , about 3cm 2 , about 4cm 2 , about 5cm2 , about 6cm 2 , about 7cm 2 , about 8cm 2 , about 9cm 2 , or about 10 cm 2 , or about 1 cm 2 Less than 1.6cm 2 Less than 2cm 2 Less than 3cm 2 Less than 4cm 2 Less than 5cm 2 Less than 6cm 2 Less than 7cm 2 Less than 8cm 2 Less than 9cm 2 Less than or about 10cm 2 It may be less than.

[0097] Moreover, one of skill in the art can readily analyze data obtained using arrays, such protocols including those found in WO9743450, WO03023058, WO03022421, WO03029485, WO03067217, WO03066906, WO03076928, WO03093810, WO03100448A1, all of which are expressly incorporated by reference.

[0098] In one embodiment, a nuclease protection assay is used to quantify RNA obtained from a tissue sample. Many different versions of nuclease protection assays are known to those skilled in the art. A common feature of such nuclease protection assays is that they involve hybridization of an antisense nucleic acid with the RNA to be quantified. The resulting hybrid double-stranded molecule is then subjected to digestion with a nuclease that is more efficient at digesting single-stranded nucleic acids compared to double-stranded molecules. The amount of antisense nucleic acid that is not digested is a measure of the amount of the target RNA species to be quantified. One example of a commercially available nuclease protection assay is the RNase protection assay provided by Ambion, Inc. (Austin, Tex.).

[0099] Measuring Gene Expression Using Proteins and Polypeptides In other embodiments, the differential expression patterns of biomarkers can be determined by measuring the levels of polypeptides encoded by such genes in cells. Methods suitable for this purpose include, but are not limited to, immunoassays, such as ELISA, RIA, FACS, dot blot, Western blot, immunohistochemistry, and antibody-based radioimaging. Protocols for performing such immunoassays are well known in the art. Other methods, such as two-dimensional SDS-polyacrylamide gel electrophoresis, can also be used. Such procedures can be used to recognize any of the polypeptides encoded by the biomarker genes described herein.

[0100] An example of a suitable method for determining the level of a target protein in a peripheral blood sample is ELISA. In one example of ELISA, an antibody capable of binding to a target protein encoded by one or more biomarker genes is immobilized on a selective surface exhibiting protein affinity, such as a well in a polystyrene or polyvinyl chloride microtiter plate. The test cell sample is then added to the well. After binding and washing to remove immune complexes resulting from non-specific binding, the bound antigen(s) can be detected. Detection can be achieved by adding a second antibody specific for the target protein and conjugated to a detectable label. Detection can also be achieved by adding the second antibody followed by a tertiary antibody having binding affinity for the secondary antibody, such tertiary antibody being conjugated to a detectable label. Cells in the peripheral blood sample can be lysed using various methods known in the art prior to addition to the microtiter plate. Appropriate extraction procedures can be used to separate the target protein from potentially interfering substances.

[0101] In another ELISA embodiment, a cell sample containing a target protein is immobilized on a well surface and then contacted with an antibody. After binding and washing to remove immune complexes resulting from non-specific binding, the bound antigen is detected. If the first antibody is conjugated with a detectable label, the immune complex can be detected directly. The immune complex can also be detected using a secondary antibody that has binding affinity for the primary antibody, and the secondary antibody is conjugated with a detectable label.

[0102] Another typical ELISA uses antibody competition in detection. In this ELISA, target protein is immobilized on the well surface. Labeled antibody is added to the well, which is allowed to bind to the target protein and is detected by its label. Here, the amount of target protein in an unknown sample is determined by mixing the sample with the labeled antibody before or during incubation with the coated well. Target protein present in the unknown sample serves to reduce the amount of antibody available for binding to the well, thus reducing the final signal.

[0103] Different formats of ELISA may have certain common features, such as coating, incubation or binding, washing to remove non-specifically bound species, and detection of bound immune complexes. For example, in coating a plate with an antigen or antibody, the wells of the plate may be incubated overnight or for a certain period of time with a solution of the antigen or antibody. The wells of the plate are then washed to remove incompletely adsorbed material. Any remaining available well surfaces are then "coated" with a non-specific protein that is antigenically neutral with respect to the test sample. Examples of such non-specific proteins include bovine serum albumin (BSA), casein, and milk powder solution. The coating allows blocking of non-specific adsorption sites on the immobilizing surface, thereby reducing background caused by non-specific binding of antisera onto the surface.

[0104] In ELISA, secondary or tertiary detection means may also be used. After the proteins or antibodies are bound to the wells, background is reduced by coating with a non-reactive material, and unbound material is removed by washing, the immobilization surface is contacted with the control and / or test clinical or biological samples under conditions effective to allow immune complex (antigen / antibody) formation. Such conditions may include, for example, diluting the antigen and antibody in a solution (such as BSA, bovine gamma globulin (BGG), and phosphate buffered saline (PBS) / Tween) and incubating the antibody and antigen for about 1-4 hours at room temperature or overnight at 49°C. Detection of the immune complex then requires the use of a labeled secondary binding ligand or antibody, or a combination of a secondary binding ligand or antibody and a labeled tertiary antibody or antibody.

[0105] After all the incubation steps in ELISA, the contact surface is washed to remove uncomplexed material.For example, the surface can be washed with a solution (such as PBS / Tween or borate buffer).After the specific immune complex is formed between the test sample and the initially bound material, washing is continued and the amount of immune complex can be determined.

[0106] To obtain detection means, the secondary or tertiary antibody may have a conjugated label to allow detection. In one embodiment, the label is an enzyme that generates color development when incubated with a suitable chromogenic substrate. Thus, for example, the primary or secondary immune complexes may be contacted and incubated with urease-conjugated antibody, glucose oxidase-conjugated antibody, alkaline phosphatase-conjugated antibody, or peroxidase-conjugated antibody for a certain period of time under conditions favorable for further immune complex formation to occur (e.g., incubation is performed in a PBS-containing solution (such as PBS-Tween) at room temperature for 2 hours).

[0107] After incubation with the labeled antibody, washing is followed to remove unbound material, and the amount of label is quantified, for example, by incubation with a chromogenic substrate (such as urea and bromocresol purple, or 2,2'-azido-di-(3-ethyl)-benzothiazoline-6-sulfonic acid (ABTS) and hydrogen peroxide if the enzyme label is a peroxidase). Quantitation can be achieved by measuring the intensity of color development, which can be done, for example, using a spectrophotometer.

[0108] Another suitable method is RIA (radioimmunoassay). One example of an RIA is based on the competition between radiolabeled and unlabeled polypeptides for binding to a limited amount of antibody. Suitable radiolabels include, but are not limited to, I 125 In one embodiment, a fixed concentration of I is used together with a dilution series of a specific antibody for the polypeptide. 125 A labeled polypeptide is incubated. When an unlabeled polypeptide is added to the system, I binding to the antibody occurs. 125 The amount of polypeptide bound to the antibody is reduced. Therefore, by constructing a standard curve, the amount of I bound to the antibody is reduced. 125 The amount of polypeptide can be expressed as a function of the concentration of unlabeled polypeptide. From this standard curve, the concentration of the polypeptide in unknown samples can be determined. Various protocols for performing RIA to measure the level of polypeptide in cell samples are well known in the art.

[0109] Suitable antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, humanized, single chain, Fab fragments, and fragments produced by a Fab expression library.

[0110] The antibody may be labeled with one or more detectable moieties that allow the antibody-antigen complex to be detected. Detectable moieties may include compositions that are detectable by spectroscopic, enzymatic, photochemical, biochemical, bioelectronic, immunochemical, electrical, optical, or chemical means. Detectable moieties include, but are not limited to, radioisotopes, chemiluminescent compounds, labeled binding proteins, heavy metal atoms, spectroscopic markers (such as fluorescent markers and dyes), magnetic labels, conjugated enzymes, mass spectrometry tags, spin labels, electron transfer donors and electron transfer acceptors, and the like.

[0111] Protein array technology is discussed in detail in Pandey and Mann (2000) and MacBeath and Schreiber (2000), each of which is expressly incorporated herein by reference. Such arrays typically contain thousands of different proteins or antibodies spotted or immobilized in small wells on a glass slide, allowing the biochemical activity and binding profile of many proteins to be examined at once. To examine protein interactions using such arrays, a labeled protein is incubated with each of the target proteins immobilized on the slide, and then it is determined which of the many proteins have bound to the labeled molecule. In certain embodiments, such technology can be used to quantify many proteins (such as biomarker proteins) in a sample.

[0112] The basic structure of a protein chip is somewhat similar to a DNA chip, using a glass or plastic surface dotted with an array of molecules. These molecules can be DNA or antibodies designed to capture proteins. A defined amount of protein is immobilized on each spot, and this immobilization is done so that some protein activity remains. Together with fluorescent markers or other detection methods that reveal on which spots these proteins are captured, protein microarrays are used as powerful tools in high-throughput proteomics and drug discovery.

[0113] The earliest and best known protein chip is the ProteinChip by Ciphergen Biosystems Inc. (Fremont, Calif.). The ProteinChip is based on the Surface Enhanced Laser Desorption Ionization (SELDI) process. Known proteins are analyzed using functional assays on the chip. For example, the chip surface may contain enzymes, receptor proteins, or antibodies that allow researchers to perform protein-protein interaction studies, ligand binding studies, or immunoassays. Using state-of-the-art ion optics and laser optics, proteins ranging from small peptides of less than 1000 Da to proteins of 300 kDa are detected by the ProteinChip system and masses are calculated based on time of flight (TOF).

[0114] The ProteinChip biomarker system is the first protein biochip-based system that allows for the performance of biomarker pattern recognition analysis. This system enables researchers to address important clinical questions by examining the proteomes derived from a variety of crude clinical samples (i.e., cells excised by laser capture microdissection, biopsies, tissues, urine, and serum). This system also utilizes Biomarker Pattern Software, which automates a pattern recognition-based statistical analysis method that correlates protein expression patterns from clinical samples with disease phenotypes.

[0115] In other embodiments, the level of a polypeptide in a sample can be determined by detecting a biological activity associated with the polypeptide. If the biological function / activity of the polypeptide is known, a suitable in vitro bioassay can be designed to assess the biological function / activity, thereby determining the amount of the polypeptide in a sample.

[0116] II. Pharmaceutical Compositions and Methods of Administration The compositions and methods described herein may include administration to a patient via any route used to administer a treatment to a patient. Such routes include, but are not limited to, intravenous, intradermal, intraarterial, intraperitoneal, intralesional, intracranial, intraarticular, intraprostatic, intrapleural, intratracheal, intranasal, intrathecal, intravitreal, intravaginal, intrarectal, external, intratumoral, intramuscular, intraperitoneal, intraocular, subcutaneous, subconjunctival, intravesical, mucosal, intrapericardial, subumbilical, intraocular, oral, external, topical, by inhalation, by injection, by infusion, by continuous infusion, by local irrigation, by catheter, by nebulizer, or by lavage, or various combinations thereof. In certain embodiments, the composition is administered to the subject by inhalation. In certain embodiments, the composition is administered to the subject as an aerosol. Another example of a route of administration is using a nebulizer. Additionally, the compositions may be administered directly to the area affected by muscle atrophy, such as by topical administration to the muscle (or to the skin or tissue overlying the muscle).

[0117] The compositions may be formulated in a pharma- ceutically acceptable composition. In certain embodiments, preservatives and / or stabilizers are included in the composition.

[0118] Further, in some embodiments, the composition comprises a disclosed compound in an amount (ng, μg, or mg) of about, at least about, or at most about 0.1, 0.2, 0.3, 0.4, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0, 10.5, 11.0, 11.5, 12.0, 12.5, 13.0, 13.5, 14.0, 14.5, 15.0, 15.5, 16.0, 16.5, 17.0, 17.5, 18.0, 18.5, 19.0, 19.5, 20.0, 21, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56 , 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 8, 99, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 441, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 7 00, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, or 1000 (or any range derivable therein), and the volume (μl or ml) containing such a compound of the present disclosure may be about, at least about, or at most about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9 ...4, 3.5, 3.6, 3.7, 3.8, 3.9, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 34、1.5、1.6、1.7、1.8、1.9、2.0、2.1、2.2、2.3、2.4、2.5、2.6、2.7、2.8、2.9、3.0、3.1、3.2、3.3、3.4、3.5、3.6、3.7、3.8、3.9、4.0、4.1、4.2、4.3、4.4、4.5、4.6、4.7、4.8、4.9、5.0、5.1、5.2、5.3、5.4、5.5、5.6、5.7、5.8、5.9、6.0、6.1、6.2、6.3、6.4、6.5、6.6、6.7、6.8、6.9、7.0、7.1、7.2、7.3、7.4、7.5、7.6、7.7、7.8、7.9、8.0、8.1、8.2、8.3、8.4、8.5、8.6、8.7、8.8、8.9、9.0, 10, 11, 12, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 441, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, The number of positions may be 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, or 1000 (or any range derivable therein). Alternatively, the composition comprises a compound at a concentration (in μM or mM) of at least about, at most about, or about 0.1, 0.2, 0.3, 0.4, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0, 10.5, 11.0, 11.5, 12.0, 12.5, 13.0, 13.5, 14.0, 14.5, 15.0, 15.5, 16.0, 16.5, 17.0, 17.5, 18.0, 18.5, 19.0, 19.5, 20.0, 21, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 7 2, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 2 90, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 441, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, The number may be 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, or 1000 (or any range derivable therein).

[0119] Moreover, such amounts may be administered to a subject in one or more doses to provide the same amount of the compound of the present disclosure per kg of the subject's body weight. For example, an amount within the range of about 1 μg / kg to about 1 mg / kg may be administered to a subject. In certain embodiments, the amount (μg / kg or mg / kg) given to a subject is about, at least about, or at most about 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0, 10.5, 11.0, 11.5, 12.0, 12.5, 13.0, 13.5, 14.0, 14.5, 15.0, 15.5, 16.0, 16.5, 17.0, 17.5, 18.0, 18.5 ,19.0,19.5,20.0,21,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 441, 450, 460, 470, 480, 490, 500, 510, 520, 5 30, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, or 1000, or any range derivable therein.Such amounts may be formulated according to a dosing basis or on a daily basis (eg, on a μg / kg body weight / day basis).

[0120] Such amount may be administered once a day, although other dosing regimens are contemplated. It is contemplated that the composition may be administered only once or multiple times. In certain embodiments, the composition may be administered once, twice, three times, four times, five times, six times, or more, or any range derivable therein. It is contemplated that the prophylactic or therapeutic regimen may be administered multiple times for 1, 2, 3, 4, 5, 6, and / or 7 days, or for 1, 2, 3, 4, or 5 weeks, and / or for 1, 2, 3, 4, or 5 weeks, and / or for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and / or 12 months, or any range derivable therein. Furthermore, any such regimen may be repeated after a certain period of time or when the symptoms of a disease or condition become pronounced or severe.

[0121] In certain embodiments, the composition or agent (such as therapeutic compound) for use in the method is suitably included in a pharma- ceutically acceptable carrier. The carrier is selected to be non-toxic and biocompatible and not to adversely affect the biological activity of the agent. The agent may be formulated into a preparation for local delivery (i.e., delivery to a specific location of the body (such as skeletal muscle or other tissue)) or systemic delivery in solid, semi-solid, gel, liquid, or gaseous forms (such as tablets, capsules, powders, granules, ointments, solutions, depots, inhalants, and injections) that allow oral, parenteral, or surgical administration in some embodiments of the present disclosure. In certain embodiments of the present disclosure, local administration of the composition by coating medical devices, topical administration, and the like are also contemplated.

[0122] Suitable carriers for parenteral delivery via injection, infusion, or irrigation, and topical delivery include distilled water, physiological phosphate buffered saline, normal Ringer's solution or lactated Ringer's solution, dextrose solution, Hank's solution, or propanediol.In addition, sterile non-volatile oils can be used as solvents or suspension media.For this purpose, any biocompatible oil can be used, including synthetic monoglycerides or diglycerides.In addition, fatty acids (such as oleic acid) are useful in the preparation of injections.The carrier and the drug can be formulated as a liquid, suspension, polymeric or non-polymeric gel, paste, or ointment.

[0123] Carriers may also include delivery vehicles for sustaining (i.e., extending, delaying, or controlling) the delivery of an agent(s) or for enhancing the delivery, uptake, stability, or pharmacokinetics of a therapeutic agent(s). Such delivery vehicles may include, by way of non-limiting examples, microparticles, microspheres, nanospheres, or nanoparticles composed of proteins, liposomes, carbohydrates, synthetic organic compounds, inorganic compounds, polymeric or copolymeric hydrogels, and polymeric micelles.

[0124] In certain embodiments, the actual dose of the composition administered to a patient or subject may be determined by physical and physiological factors (such as body weight, severity of the condition, type of disease being treated, previous or concurrent therapeutic interventions, idiopathic disease of the patient, etc.), as well as the route of administration. The medical professional responsible for administration will, in any event, determine the concentration of active ingredient(s) in the composition and the dose(s) appropriate for the individual subject.

[0125] In certain embodiments, the pharmaceutical composition may contain, for example, at least about 0.1% of an active agent (such as isolated exosomes, associated lipid nanovesicles, or exosomes or nanovesicles loaded with a therapeutic or diagnostic agent). In other embodiments, the active agent may comprise from about 2% to about 75% of the weight of the unit, or from about 25% to about 60%, for example, any range derivable therein. In other non-limiting examples, the dosage can be about 1 microgram / kg / body weight, about 5 micrograms / kg / body weight, about 10 micrograms / kg / body weight, about 50 micrograms / kg / body weight, about 100 micrograms / kg / body weight, about 200 micrograms / kg / body weight, about 350 micrograms / kg / body weight, about 500 micrograms / kg / body weight, about 1 milligram / kg / body weight, about 5 milligrams / kg / body weight, about 10 milligrams / kg / body weight, about 50 milligrams / kg / body weight, about 100 milligrams / kg / body weight, about 200 milligrams / kg / body weight, about 350 milligrams / kg / body weight, about 500 milligrams / kg / body weight to about 1000 mg / kg / body weight or more per administration, and any range derivable therein. Non-limiting examples of ranges that can be derived from the numbers recited herein include doses ranging from about 5 micrograms / kg / body weight to about 100 mg / kg / body weight, from about 5 micrograms / kg / body weight to about 500 milligrams / kg / body weight, etc.

[0126] Solutions of the pharmaceutical compositions can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, mixtures thereof, and oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

[0127] In certain embodiments, pharmaceutical compositions are advantageously administered in the form of injectable compositions as liquid solutions or suspensions. Solid forms suitable for obtaining liquid solutions or suspensions before injection can also be prepared. Such preparations can also be emulsified. Typical compositions for such purposes include pharmaceutically acceptable carriers. For example, the composition can include up to 10 mg, 25 mg, 50 mg, or up to about 100 mg of human serum albumin per milliliter of phosphate buffered saline. Other pharmaceutically acceptable carriers include aqueous solutions, non-toxic pharmaceutical additives (including salts, preservatives, buffers), and the like.

[0128] Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils, and injectable organic esters (such as ethyl oleate). Aqueous carriers include water, alcoholic / aqueous solutions, saline solutions, parenteral vehicles (such as sodium chloride), Ringer's dextrose, and the like. Intravenous vehicles include fluid and nutrient replenishers. Preservatives include antimicrobial agents, antifungal agents, antioxidants, chelating agents, and inert gases. The pH and exact concentration of the various components of the pharmaceutical composition are adjusted according to well-known parameters.

[0129] Additional formulations are suitable for oral administration. Oral formulations contain typical pharmaceutical excipients (e.g., pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate, and the like). The compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations, or powders.

[0130] In another embodiment, the pharmaceutical composition may include a typical pharmaceutical preparation. Administration of the pharmaceutical composition according to certain embodiments may be via any common route, provided that the target tissue is available via that route. This may include oral, nasal, buccal, rectal, vaginal, or topical routes. Alternatively, administration may be by orthotopic, intradermal, subcutaneous, intramuscular, intraperitoneal, or intravenous injection. Such compositions would be administered standardly as pharma- ceutical acceptable compositions containing physiologically acceptable carriers, buffers, or other excipients. For the treatment of pulmonary conditions, aerosol delivery may be used. The volume of the aerosol is about 0.01 ml to 0.5 ml.

[0131] The effective amount of the pharmaceutical composition is determined based on the intended purpose. The term "unit dose" or "dose" refers to a physically discrete unit suitable for use in a subject, each unit containing a predetermined amount of the pharmaceutical composition calculated to obtain the desired response discussed above upon its administration (i.e., by an appropriate route and treatment regimen). The dosage is along the lines of both number of treatments and unit dose, depending on the protection or effect desired.

[0132] The precise amount of a pharmaceutical composition also depends on the judgment of the health care practitioner and is individual to each individual. Factors affecting the dosage include the physical and clinical condition of the patient, the route of administration, the intended therapeutic objective (e.g., palliative or curative), and the potency, stability, and toxicity of the particular therapeutic agent.

[0133] Various combinations of compounds of the present disclosure and / or other conventional therapeutic agents for muscular dystrophy or muscle atrophy or cachexia or sarcopenia or myopathy may be used. For example, a first therapeutic compound or agent is "A" and a second therapeutic compound or agent is "B", which may be combined and / or excluded in non-limiting manners as described below. TIFF2025000907000024.tif18128

[0134] The administration of the therapeutic compound or agent to the patient will follow the general administration protocol of such compounds, taking into account the toxicity, if any, of the treatment. It is expected that the treatment cycle will be repeated as necessary. It is also contemplated that various standard treatments as well as surgical interventions may be applied in combination with the described treatment.

[0135] In some embodiments, the methods of the present disclosure include an additional treatment. In some embodiments, the additional treatment includes a corticosteroid. Examples of corticosteroids include prednisone, prednisolone, beclomethasone, fluticasone, methylprednisolone, cortisone, hydrocortisone, triamcinolone, methylprednisolone, and dexamethasone. In some embodiments, the additional treatment includes a cardiac drug, such as an angiotensin-converting enzyme (ACE) inhibitor or a beta-blocker. Examples of ACE inhibitors include benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, and trandolapril. Examples of beta-blockers include acebutolol hydrochloride, atenolol, betaxolol hydrochloride, bisoprolol fumarate, carteolol hydrochloride, esmolol hydrochloride, metoprolol, penbutolol sulfate, nadolol, nebivolol, pindolol, propranolol, timolol maleate, sotalol hydrochloride, carvedilol, and labetalol hydrochloride.

[0136] In some embodiments, the additional therapeutic treatment comprises exercise, low-impact exercise, physical therapy, physical assistive devices (such as wheelchairs, braces, or crutches), and / or occupational therapy. In some embodiments, the additional therapeutic treatment comprises creatine supplementation.

[0137] III.Chemical definition Below are provided various chemical definitions associated with such compounds. The term "water soluble" as used herein means that the compound dissolves in water to the extent of at least 0.010 moles / liter or that the compound is classified as soluble according to prior literature.

[0138] As used herein, the term "nitro" means -NO2. The term "halo" refers to -F, -Cl, -Br, or -I. The term "mercapto" means -SH. The term "cyano" means -CN. The term "azido" means -N3. The term "silyl" means -SiH3. The term "hydroxyl" means -OH.

[0139] The term "alkyl," alone or as part of another substituent, means, unless otherwise specified, a straight (i.e., unbranched) or branched carbon chain, which may be fully saturated, monounsaturated, or polyunsaturated. Unsaturated alkyl groups are those that have one or more double or triple bonds. Saturated alkyl groups include those that have one or more carbon-carbon double bonds (alkenyl) and those that have one or more carbon-carbon triple bonds (alkynyl). The groups -CH3 (Me), -CH2CH3 (Et), -CH2CH2CH3 (n-Pr), -CH(CH3)2 (iso-Pr), -CH2CH2CH2CH3 (n-Bu), -CH(CH3)CH2CH3 (sec-butyl), -CH2CH(CH3)2 (iso-butyl), -C(CH3)3 (tert-butyl), and -CH2C(CH3)3 (neo-pentyl) are all non-limiting examples of alkyl groups.

[0140] The term "heteroalkyl", alone or in combination with another term, means, unless otherwise stated, a straight or branched chain having at least one carbon atom and at least one heteroatom selected from the group consisting of O, N, S, P, and Si. In certain embodiments, the heteroatom is selected from the group consisting of O and N. The heteroatom(s) may be placed at any interior position of the heteroalkyl group or at the position at which the alkyl group is attached to the remainder of the molecule. Up to two heteroatoms may be consecutive. The following groups are all non-limiting examples of heteroalkyl groups: trifluoromethyl, -CH2F, -CH2Cl, -CH2Br, -CH2OH, -CH2OCH3, -CH2OCH2CF3, -CH2OC(O)CH3, -CH2NH2, -CH2NHCH3, -CH2N(CH3)2, -CH2CH2Cl, -CH2CH2OH, CH2CH2OC(O)CH3, -CH2CH2NHCO2C(CH3)3, and -CH2Si(CH3)3.

[0141] The terms "cycloalkyl" and "heterocyclyl," alone or in combination with other terms, refer to cyclic versions of "alkyl" and "heteroalkyl," respectively. Additionally, for heterocyclyl, a heteroatom can occupy the position at which the heterocycle is attached to the remainder of the molecule.

[0142] The term "aryl" refers to a polyunsaturated aromatic hydrocarbon substituent. Aryl groups can be monocyclic or polycyclic (e.g., 2-3 rings fused together or linked by a covalent bond). The term "heteroaryl" refers to an aryl group containing 1-4 heteroatoms selected from N, O, and S. Heteroaryl groups can be attached to the remainder of the molecule through a carbon atom or a heteroatom. Examples of aryl and heteroaryl groups include, but are not limited to, phenyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyl-4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5 ...

[0033] Examples of aryl and heteroaryl ring systems include aryl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl, 1-isoquinolyl, 5-isoquinolyl, 2-quinoxalinyl, 5-quinoxalinyl, 3-quinolyl, and 6-quinolyl. Substituents for each of the above noted aryl and heteroaryl ring systems are selected from the group of acceptable substituents described below.

[0143] Various groups are described herein as being substituted or unsubstituted (i.e., optionally substituted). Optionally substituted groups may contain one or more substituents independently selected from halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxy, oxo, carbamoyl, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, alkoxy, alkylthio, alkylamino, (alkyl)2amino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl. In certain embodiments, the optional substituents may be further substituted with one or more substituents independently selected from halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxy, carbamoyl, unsubstituted alkyl, unsubstituted heteroalkyl, alkoxy, alkylthio, alkylamino, (alkyl)2amino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, unsubstituted cycloalkyl, unsubstituted heterocyclyl, unsubstituted aryl, or unsubstituted heteroaryl. Examples of optional substituents include, but are not limited to, -OH, oxo (=O), -Cl, -F, Br, C 1-4 Alkyl, phenyl, benzyl, -NH2, -NH(C 1-4 alkyl), -N(C 1-4 alkyl)2, -NO2, -S(C 1-4 Alkyl), -SO2(C 1-4 alkyl), -CO2(C 1-4 alkyl), and -O(C 1-4 alkyl).

[0144] The term "alkoxy" refers to a group having the structure -OR', where R' is an optionally substituted alkyl or cycloalkyl group. The term "heteroalkoxy" similarly refers to a group having the structure -OR, where R is a heteroalkyl or heterocyclyl.

[0145] The term "amino" refers to a group having the structure -NR'R", where R' and R" are independently hydrogen or an optionally substituted alkyl, heteroalkyl, cycloalkyl, or heterocyclyl group. The term "amino" includes primary, secondary, and tertiary amines.

[0146] The term "oxo" as used herein means an oxygen attached to a carbon atom with a double bond.

[0147] The term "alkylsulfonyl" as used herein means a moiety having the formula -S(O2)-R', where R' is an alkyl group. R' can have a specified number of carbons (e.g., "C1-4 alkylsulfonyl").

[0148] The term "pharmaceutical acceptable salt" as used herein refers to a salt of the compound of the present invention that is substantially non-toxic to living organisms. Typical pharmaceutical acceptable salts include salts prepared by reacting the compound of the present invention with an inorganic or organic acid or an organic base, depending on the substituents present on the compound of the present invention.

[0149] Examples of inorganic acids that can be used to prepare pharmaceutically acceptable salts include, but are not limited to, hydrochloric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, phosphorous acid, and the like. Examples of organic acids that can be used to prepare pharmaceutically acceptable salts include aliphatic mono- and dicarboxylic acids (such as oxalic acid, carbonic acid, citric acid, succinic acid, etc.), phenyl heteroatom-substituted alkanoic acids, aliphatic and aromatic sulfuric acids, and the like. Thus, pharmaceutically acceptable salts prepared from inorganic or organic acids include hydrochloride, hydrobromide, nitrate, sulfate, pyrosulfate, bisulfate, sulfite, bisulfate, phosphate, monohydrogen phosphate, dihydrogen phosphate, metaphosphate, pyrophosphate, hydroiodide, hydrofluoride, acetate, propionate, formate, oxalate, citrate, lactate, p-toluenesulfonate, methanesulfonate, maleate, and the like.

[0150] Suitable pharma- ceutically acceptable salts may also be formed by reacting the agents of the invention with organic bases, such as methylamine, ethylamine, ethanolamine, lysine, ornithine, and the like. Pharmaceutically acceptable salts include salts formed between carboxyl or sulfonic acid groups found in some of the compounds of the invention and inorganic cations, such as sodium, potassium, ammonium, or calcium, or organic cations, such as isopropylammonium, trimethylammonium, tetramethylammonium, and imidazolium.

[0151] It will be recognized that the particular anion or cation forming a part of any salt of this invention is not critical, so long as the salt is pharmacologically acceptable as a whole.

[0152] Additional examples of pharma- ceutically acceptable salts and their methods of preparation and use are provided in Handbook of Pharmaceutical Salts: Properties, Selection and Use (2002), which is incorporated herein by reference.

[0153] An "isomer" of a compound is another compound in which each molecule contains the same constituent atoms as the compound, but the arrangement of those atoms in three dimensions is different. Unless otherwise specified, the compounds described herein are intended to include their isomers. EXAMPLES

[0154] IV. Working Examples The following examples are included to demonstrate preferred embodiments of the invention. Those of skill in the art will appreciate that the procedures disclosed in the examples follow representative procedures discovered by the inventors to work well in the practice of the invention, and therefore may be considered to constitute preferred modes for practicing the invention. However, those of skill in the art will appreciate, in light of this disclosure, that many modifications can be made to the specific embodiments disclosed that will still yield the same or similar results without departing from the spirit and scope of the invention.

[0155] Example 1 In C3KO muscle, exercise does not properly induce myofibrillar gene expression. Limb-girdle muscular dystrophy type 2A / R1 / D1 (LGMD2A / R1 / D1) is caused by mutations in the gene encoding the non-lysosomal cysteine ​​protease calpain 3 (CAPN3). Muscles from patients and mice lacking CAPN3 have greatly reduced muscle mass, but unlike dystrophinopathies, their sarcolemma is stable, suggesting that the pathogenesis of LGMD2A is distinct from that of dystrophinopathies. CAPN3 localizes to several intracellular compartments, including the triad, where it is activated by calmodulin and plays an undetermined role in calcium release. Our previous studies have shown that muscles from CAPN3 knockout (C3KO) mice fail to grow after atrophy development. This is accompanied by impaired Ca calmodulin-dependent protein kinase II (CaMKII) signaling. While the expression of several slow-twitch genes (e.g., Myl2, Mybph, and Ckmt2) is increased in muscles of WT mice subjected to exercise training, these adaptive changes to exercise do not occur in muscles of C3KO mice. Similarly, myofibrillar, cytoskeletal, mitochondrial, and lipid metabolism genes are also slowed in C3KO mice. Consistent with mouse studies, preferential involvement of slow-twitch fibers was observed in pathology in LGMD2A biopsies. Figure 8 shows the signaling pathways induced by exercise and activation of gene transcription. Figure 9 shows that limb-girdle muscular dystrophy type 2A lacks CAPN3, which reduces CAMK signaling and blunts downstream gene transcription. Gene expression levels of sarcomere-associated proteins (Myl2 (myosin regulatory light chain 2, cardiac muscle, slow muscle), Ckmt2 (mitochondrial creatine kinase), Myom3 (myomesin 3), and Myo18b (myosin 18b)) in plantaris muscle were verified by RT-PCR. The graph compares the expression levels of the exercised (running) group with those of the non-exercised (immobile) control (Figure 10). Genes in this RNAseq dataset were validated by qPCR. Myl2, Ckmt2, and Lpl are all downstream targets of CAMKIIβ.

[0156] Example 2 AMBMP reverses the blockade of CAMKII signaling and treats LGMD2A. Enhancing the expression of genes induced by CaMKII represents a novel target for LGMD2A. Compounds that activate these slow-twitch genes may have therapeutic potential for LGMD2A / R1 / D1. Furthermore, these studies have identified pathways involved in normal muscle remodeling (e.g., promoting growth after atrophy and promoting oxidative metabolism). Drugs that act on this pathway may be beneficial for many types of muscle conditions (such as cancer cachexia, sarcopenia due to aging and prolonged bed rest). Previous studies have identified AMBMP (Formula VI) as a drug to reverse the blockade of CAMKII signaling and treat LGMD2A, as discussed in WO2017 / 208211.

[0157] FIG. 11 shows that AMBMP increases slow muscle fiber diameter. The average cross-sectional area (CSA) was measured in muscle cross sections after staining for fiber type. Although an increase occurs in both fiber types, only the cross-sectional area of ​​slow muscle fibers is significantly increased. A) C3KO mice intraperitoneally injected with AMBMP hydrochloride (7.5 mg / kg / day) for 14 days. B) C3KO mice treated with AMBMP hydrochloride (7.5 mg / kg / day) by subcutaneous (subQ) injection for 14 days. C3KO mice intraperitoneally injected with AMBMP hydrochloride (7.5 mg / kg / day) for 14 days have improved mitochondrial function compared to (C) controls (mice not treated with AMBMP). * p<0.05, bar=SD.

[0158] As shown in Figure 12, C3KO mice treated with AMBMP hydrochloride (intraperitoneal injection) for 2 weeks increased mitochondrial content in a dose-dependent manner. One set of C3KO mice was intraperitoneally injected with AMBMP hydrochloride (7.5 mg / kg / day) for 14 days, another set of C3KO mice was intraperitoneally injected with AMBMP hydrochloride (15 mg / kg / day) for 14 days, and a control set of C3KO mice was not treated with AMBMP. The percentage of fibers with high mitochondrial content and the percentage of fibers with intermediate mitochondrial content increased in a dose-dependent manner with AMBMP treatment, and the percentage of fibers with low mitochondrial content decreased in a dose-dependent manner with AMBMP treatment (Figure 12A). Figure 12B shows muscle sections stained for NADH (darker staining indicates higher oxidative capacity). Quantification of NADH staining for plantaris muscle from mice treated with AMBMP (either 7.5 mg / kg or 15 mg / kg for 2 weeks (wk)) is shown as the ratio of FOG to FG fibers. * p<0.05. AMBMP treatment increased mitochondrial content in a dose-dependent manner.

[0159] As shown in FIG. 13, AMBMP treatment improves exercise capacity. Mice were subjected to endurance training for 3 weeks, during which the mice were treated. Exercise capacity was compared before and after the exercise condition. Wild-type (WT) mice were not treated with AMBMP. The WT mice show the training effect. One set of C3KO mice was not treated with AMBMP. This set of C3KO mice does not show the training effect. Another set of C3KO mice was intraperitoneally injected with AMBMP hydrochloride (7.5 mg / kg / day) for 14 days. This set of C3KO mice shows the training effect.

[0160] As shown in Figure 14, CaMKIIβ activity is normalized in C3KO mice treated with AMBMP, but AKT or AMPK signaling is not affected. CaMKIIβ activity is increased in C3KO and WT mice intraperitoneally injected with AMBMP hydrochloride at 7.5 mg / kg / day for 2 weeks compared to the respective untreated controls (Figure 14A). CaMKIIβ activity is increased in C3KO mice intraperitoneally injected with AMBMP hydrochloride at 7.5 mg / kg / day for 2 weeks compared to the untreated controls, without affecting AKT or AMPK signaling (Figure 14B).

[0161] Figure 15 shows that AMBMP alters the percentage of slow twitch fibers in Capn3- / - muscles. A) Statistically significant change in the % of slow twitch myosin heavy chain positive fibers in soleus muscles from calpainopathy mice treated with AMBMP subQ once daily at 30 mg / kg for 2 weeks. B) Slow twitch myosin staining of cross sections of calpainopathy muscles treated with AMBMP once daily at 7.5 mg / kg for 2 weeks.

[0162] Example 3 Biological activity data for AMBMP analogs 1-6, AMBMP analog 17, AMBMP analog 18, and AMBMP analog 25. Figure 16A shows the dose-dependent effects of AMBMP analogs 1-6, AMBMP analog 17, AMBMP analog 18, and AMBMP analog 25 on endogenous myosin light chain 2 (Myl2) expression in C2C12 cells.

[0163] Table 1 shows the effects of 2.5 μM AMBMP analogs 1-6, AMBMP analog 8, AMBMP analog 17, AMBMP analog 21, AMBMP analog 25, AMBMP analog 38, AMBMP analog 39, and AMBMP analog 40 on the relative expression of Myl2 to GAPDH (housekeeping control gene) in C2C12 cells. Myl2 is a marker of CaMKIIβ activity. Table 1. Myl2 expression in C2C12 cells TIFF2025000907000025.tif76128

[0164] AMBMP analog 3 was tested in vivo for its ability to induce CaMKIIβ activation and Myl2 gene expression. Mice were intraperitoneally injected with AMBMP analog 3 at 10 mg / kg. Skeletal muscle was harvested 2 hours, 4 hours, and 6 hours after injection. Mice injected with DMSO were used as a control group. Figure 16B shows CaMKIIβ activation in mouse skeletal muscle, which is indicated by phosphorylated CaMKIIβ (P-CaMKII or P-CaMK) expression assessed by Western blot using anti-phosphorylated CaMKIIβ antibody. Figure 16C shows the level of P-CaMK normalized by gel loading. Figure 16D shows Myl2 expression in plantaris muscle assessed by RT-PCR and normalized with GAPDH as a housekeeping control gene (each bar corresponds to one mouse).

[0165] AMBMP analog 40 was tested in C2C12 myogenic cells for its ability to induce the expression of Myl2. C2C12 cells were treated with AMBMP or AMBMP analog 40 (concentrations indicated on the graph) for 48 h. DMSO was used as a negative control. Expression of Myl2 was assessed by RT-PCR and normalized with GAPDH as a housekeeping control gene. As shown in Figure 16E, analog 40 increases Myl2 expression 2.5-2.9 fold. Analog 40 is also better tolerated by cells compared to AMBMP (data not shown).

[0166] Example 4 Synthesis of AMBMP Analogs. AMBMP analogs were synthesized according to one or more of the steps of General Scheme I, General Scheme II, General Scheme III, and / or General Scheme IV (FIG. 17).

[0167] AMBMP analogue 3 (Figure 1C) Method 1: AMBMP analog 3 was synthesized according to Scheme I 4,6-Dichloropyrimidin-2-amine was reacted with an equivalent amount of benzo[d][1,3]dioxol-5-ylmethanamine in t-butanol. The reaction product was further reacted with an equivalent amount of (3-hydroxyphenyl)boronic acid in the presence of Pd(PPh3)4 in a column. The resulting product was purified by silica gel chromatography on a Combiflash Rf200 using a hexane-EtOAc step gradient (95:5 to 80:20) over 30 min. The fractions corresponding to the product peak were combined and concentrated using a rotary evaporator to obtain AMBMP analog 3. The logP of AMBMP analog 3 is 2.47. The product was characterized by nuclear magnetic resonance spectroscopy (NMR).

[0168] Method 2: AMBMP analog 3 was synthesized according to Scheme IV N4-(benzo[d][1,3]dioxol-5-ylmethyl)-6-chloropyrimidine-2,4-diamine (500 mg, 1.79 mmol, 1.0 equiv), ((3-hydroxyphenyl)boronic acid (493.80 mg, 3.58 mmol, 2.0 equiv), sodium carbonate (758.89 mg, 7.16 mmol, 4.0 equiv), and tetrakis(triphenylphosphine)-palladium(0) (1034.25 mg, 0.90 mmol, 0.5 equiv) were added to a 125 mL glass pressure vessel and suspended in 25 mL of toluene-ethanol (2:1). The reaction mixture was incubated at 110 °C for 72 h under a nitrogen atmosphere. The mixture was stirred for 2 h. The crude product was cooled and then filtered through celite, and the filtrate was collected and concentrated under reduced pressure. The concentrate was then washed with NaHCO3 and extracted with ethyl acetate (4 x 30 mL). The organic layer was collected, dried over Na2SO4, and purified by flash chromatography using a gradient method with DCM and methanol. The product-containing fractions were combined and concentrated under reduced pressure to give the final product (3-(2-amino-6-((benzo[d][1,3]dioxol-5-ylmethyl)amino)pyrimidin-4-yl)phenol) (white powder, 50 mg, 8.3% yield). TIFF2025000907000026.tif32164

[0169] AMBMP analogue 4 (Figure 1D) AMBMP analog 4 was synthesized according to Scheme I. 4,6-Dichloropyrimidin-2-amine was reacted with an equivalent amount of benzo[d][1,3]dioxol-5-ylmethanamine in t-butanol. The reaction product was further reacted with an equivalent amount of (3-(ethoxy)phenyl)boronic acid in the presence of Pd(PPh3)4 in a column. The resulting product was purified by silica gel chromatography on a Combiflash Rf200 using a hexane-EtOAc step gradient (95:5→80:20) over 30 min. The fractions corresponding to the product peak were combined and concentrated using a rotary evaporator to give AMBMP analog 4 in 60% yield. The product was characterized by NMR.

[0170] Alternatively, AMBMP analog 4 was synthesized according to Scheme IV. TIFF2025000907000027.tif31164

[0171] AMBMP analogue 5 (Figure 1E) AMBMP analog 5 was synthesized according to Scheme I. 4,6-Dichloropyrimidin-2-amine was reacted with an equivalent amount of benzo[d][1,3]dioxol-5-ylmethanamine in t-butanol. The reaction product was further reacted with an equivalent amount of (3-(propoxy)phenyl)boronic acid in the presence of Pd(PPh3)4 in a column. The resulting product was purified by silica gel chromatography on a Combiflash Rf200 using a hexane-EtOAc step gradient (95:5→80:20) over 30 min. The fractions corresponding to the product peak were combined and concentrated using a rotary evaporator to give AMBMP analog 5 in 48% yield. The product was characterized by NMR.

[0172] Alternatively, AMBMP analog 5 was synthesized according to Scheme IV. TIFF2025000907000028.tif30164

[0173] AMBMP analogue 6 (Figure 1F) AMBMP analog 6 was synthesized according to Scheme I. 4,6-Dichloropyrimidin-2-amine was reacted with an equivalent amount of benzo[d][1,3]dioxol-5-ylmethanamine in t-butanol. The reaction product was further reacted with an equivalent amount of (3-(tert-butoxy)phenyl)boronic acid in the presence of Pd(PPh3)4 in a column. The resulting product was purified by silica gel chromatography on a Combiflash Rf200 using a hexane-EtOAc step gradient (95:5→80:20) over 30 min. The fractions corresponding to the product peak were combined and concentrated using a rotary evaporator to give analog 6 in 15% yield. The product was characterized by NMR.

[0174] Alternatively, AMBMP analog 6 was synthesized according to Scheme IV. TIFF2025000907000029.tif31164

[0175] AMBMP analogue 7 (Figure 1G) AMBMP analog 7 was synthesized according to Scheme III. AMBMP analog 7 was obtained by reacting AMBMP analog 3 with an equivalent amount of 2-methoxyethan-1-ol using PPh3 and diethyl azodicarboxylate (DEAD). The LogP of AMBMP analog 7 is 2.90.

[0176] AMBMP analogue 8 (Figure 1H) AMBMP analog 8 was synthesized according to Scheme III. AMBMP analog 3 was reacted with an equivalent amount of 3-[2-(2-methoxyethoxy)ethoxy]propan-1-ol using PPh3 and diethyl azodicarboxylate (DEAD) to give AMBMP analog 8. The logP of AMBMP analog 8 is 2.86.

[0177] Alternatively, AMBMP analog 8 was synthesized as follows. TIFF2025000907000030.tif20159

[0178] AMBMP analogue 9 (Figure 1I) AMBMP analog 9 was synthesized according to Scheme III. AMBMP analog 3 was reacted with an equivalent amount of 2-(2-aminoethoxy)ethan-1-ol using PPh3 and diethyl azodicarboxylate (DEAD) to give AMBMP analog 9. The logP of AMBMP analog 9 is 1.70.

[0179] AMBMP analog 17 (Figure 1Q) AMBMP analog 17 was synthesized according to Scheme I. 4,6-Dichloropyrimidin-2-amine was reacted with an equivalent amount of benzo[d][1,3]dioxol-5-ylmethanamine in t-butanol. The reaction product was further reacted with an equivalent amount of (4-(trifluoromethoxy)phenyl)boronic acid in the presence of Pd(PPh3)4 in a column. The resulting product was purified by silica gel chromatography on a Combiflash Rf200 by using a hexane-EtOAc step gradient (95:5→80:20) over 30 min. The fractions corresponding to the product peak were combined and concentrated using a rotary evaporator to give AMBMP analog 17 in 48% yield. The product was characterized by NMR and mass spectrometry (MS).

[0180] Alternatively, AMBMP analog 6 was synthesized according to Scheme IV. TIFF2025000907000031.tif34164

[0181] AMBMP analogue 18 (Figure 1R) 200 mg (0.72 mmol) of 4,6-dichloropyrimidin-2-amine was added to a 15 mL glass pressure tube and the 4,6-dichloropyrimidin-2-amine was reacted with an equivalent amount of benzo[d][1,3]dioxol-5-ylmethanamine in t-butanol. The resulting product was reacted with 217 mg (1.43 mmol) of (4-methoxyphenyl)boronic acid, 305 mg (2.88 mmol) of Na2CO3, 416 mg (0.36 mmol) of Pd(PPh3)4 and suspended in 10 mL of ACN-H2O (1:1) under nitrogen atmosphere. The reaction mixture was stirred at 140 °C for 48 h and then cooled to room temperature. The mixture was filtered through a short silica plug and washed with EtOAc. The resulting crude product was washed with NaHCO3 and extracted with EtOAc (2 x 10 mL). The organic phases were combined, dried (MgSO4) and purified using a Combiflash R column with a hexane-EtOAc step gradient (95:5 to 80:20) over 30 min. f The product was purified by silica gel chromatography at 200. The fractions corresponding to the product peak were combined and concentrated using a rotary evaporator to give 151 mg of AMBMP analog 18 in 60% yield. The product was characterized by NMR and MS.

[0182] AMBMP analogue 40 (Figure 1W) AMBMP analog 40 was synthesized according to Scheme IV. N4-(benzo[d][1,3]dioxol-5-ylmethyl)-6-chloropyrimidine-2,4-diamine (100 mg, 0.36 mmol, 1.0 equiv), (3-hydroxy-5-methoxyphenyl)boronic acid (120.81 mg, 0.72 mmol, 2.0 equiv), sodium carbonate (152.46 mg, 1.44 mmol, 4.0 equiv), and tetrakis(triphenylphosphine)-palladium(0) (207.78 mg, 0.18 mmol, 0.5 equiv) were added to a 15 mL glass pressure vessel and suspended in 5 mL of toluene-ethanol (2:1). The reaction mixture was stirred at 110 °C for 72 h under nitrogen atmosphere. The crude product was cooled and then filtered through celite, and the filtrate was collected and concentrated under reduced pressure. The concentrate was then washed with NaHCO3 and extracted with ethyl acetate (4 x 30 mL). The organic layer was collected, dried over Na2SO4, and purified by flash chromatography using a gradient method with hexane and ethyl acetate. The product-containing fractions were combined and concentrated under reduced pressure to give the final product (3-(2-amino-6-((benzo[d][1,3]dioxol-5-ylmethyl)amino)pyrimidin-4-yl)-5-methoxyphenol) (yellowish powder, 38.21 mg, 28.8% yield). TIFF2025000907000032.tif40164

[0183] All of the methods disclosed and claimed herein can be designed and executed without undue experimentation in light of the present disclosure. While the compositions and methods of the present invention have been described in terms of preferred embodiments, it will be apparent to those skilled in the art that changes can be applied to such methods and to the steps or sequence of steps of the methods described herein without departing from the concept, spirit, and scope of the invention. More specifically, it will be apparent that certain agents that are both chemically and physiologically related can be substituted for the agents described herein while achieving the same or similar intended results. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope, and concept of the invention as defined by the appended claims.

Claims

1. Formula VII A compound having the chemical structure In the formula, R １ and R ２ is independently H, alkyl, substituted alkyl, aryl, or R １ and R ２ taken together form a 4- to 6-membered heterocycle; R ３ and R ４ is independently selected from H, alkyl, substituted alkyl, aryl, or R ３ and R ４ is a bond forming a 5-membered heterocyclic ring, or R ３ and R ４ taken together form a six-membered heterocycle; R １６ and R １７ is independently selected from H, alkyl, substituted alkyl, aryl, or R １６ and R １７ taken together form a 4- to 8-membered cycloalkyl or heterocyclic ring; １８ is independently alkyl, substituted alkyl, heteroalkyl, cycloalkyl, aryl, or heteroaryl; each R １９ is independently alkyl, substituted alkyl, heteroalkyl, cycloalkyl, aryl, or heteroaryl; h is 0, 1, 2, 3, or 4; k is 1, 2, 3, 4, or 5; Formula VII is Formula VI is not the compound.

2. Formula I The compound of claim 1 having the chemical structure: In the formula, R １ and R ２ is independently H, alkyl, substituted alkyl, aryl, or R １ and R ２ taken together form a 4- to 6-membered heterocycle; R ３ and R ４ is independently selected from H, alkyl, substituted alkyl, aryl, or R ３ and R ４ is a bond forming a 5-membered heterocyclic ring, or R ３ and R ４ taken together form a six-membered heterocycle; R ５ and R ６ is independently selected from H, alkyl, substituted alkyl, aryl, or R ５ and R ６ is a bond forming a 5-membered heterocyclic ring, or R ５ and R ６ taken together form a 6-membered heterocycle; X is a group having the chemical structure of Formula II, Formula III, Formula IV, or Formula V: In the formula, Z is H, alkyl, substituted alkyl, aryl, OR ７ , or N.R. ８ R ９ and R ７ is H, alkyl, haloalkyl, substituted alkyl, or aryl; R ８ and R ９ is independently H, alkyl, substituted alkyl, aryl, or R ８ and R ９ together form a 4- to 6-membered heterocycle, J １ is H, alkyl, or OR １０ is selected from; １０ is H, alkyl, haloalkyl, substituted alkyl, aryl, or ((CH ２ ) ｎ O) ｐ CH ２ CH ２ R １１ (n is 1, 2, or 3; p is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10); R １１ OH, NH ２ or alkoxy, J ２ is H, alkyl, or OR １２ is selected from; １２ is H, alkyl, haloalkyl, substituted alkyl, aryl, or ((CH ２ ) ｎ O) ｐ CH ２ CH ２ R １３ (n is 1, 2, or 3; p is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10); R １３ OH, NH ２ or alkoxy; In the formula, M is O, NH, or CH ２ and In the formula, R １４ is H or alkoxy, R １５ is H or alkoxy.

3. R １ is H, and R ２ is H, and R ３ is H, and R ４ is H, and R ５ and R ６ The compound of claim 2, wherein is a bond forming a 5-membered heterocycle and X is of formula II.

4. R １ is H, and R ２ is H, and R ３ is H, and R ４ is H, and R ５ and R ６ is a bond forming a 5-membered heterocycle, X is of formula II, Z is H, and J ２ is H and J １ But, OR １０ 3. The compound of claim 2,

5. R １０ But H, CF ３ , C.H. ２ CH ３ , CH(CH ３ ) ２ , C.H. ２ CH ２ CH ３ , C.H. ２ CH ２ OCH ３ , C.H. ２ CH ２ OCH ２ CH ２ N.H. ２ , C.H. ２ CH ２ OCH ２ CH ２ OCH ２ CH ２ OCH ３ , C.H. ２ N.H. ２ , C.H. ２ CH ２ N.H. ２ , or C.H. ２ CONH ２ 5. The compound of claim 4,

6. The compound of claim 1, which is AMBMP analog 1, AMBMP analog 2, AMBMP analog 3, AMBMP analog 4, AMBMP analog 5, AMBMP analog 6, AMBMP analog 8, AMBMP analog 17, AMBMP analog 21, AMBMP analog 25, AMBMP analog 38, AMBMP analog 39, or AMBMP analog 40.

7. A composition comprising a compound according to any one of claims 1 to 6, further comprising a pharma- ceutically acceptable carrier.

8. 13. A method of treating muscular dystrophy in a subject, comprising administering to the subject an effective amount of a compound according to any one of claims 1 to 6, or a pharma- ceutically acceptable salt or solvate thereof.

9. 9. The method of claim 8, wherein the type of muscular dystrophy is limb-girdle muscular dystrophy.

10. 9. The method of claim 8, wherein the type of muscular dystrophy is limb-girdle muscular dystrophy type 2A.

11. 13. A method of treating muscle atrophy in a subject, comprising administering to the subject an effective amount of a compound according to any one of claims 1 to 6, or a pharma- ceutical acceptable salt or solvate thereof.

12. 12. The method of claim 11, wherein the subject has been determined to have or be at risk for muscle atrophy.

13. The method according to any one of claims 11 to 12, wherein the subject is being tested for muscle atrophy or a disease that causes or is associated with muscle atrophy.

14. The method of any one of claims 11 to 13, wherein the subject has previously been treated with one or more treatments for muscle wasting.

15. 15. The method of claim 14, wherein one or more of the treatments for muscle wasting is prescribed chemotherapy.

16. 10. A method for treating cachexia or sarcopenia in a subject, comprising administering to the subject an effective amount of a compound according to any one of claims 1 to 6, or a pharma- ceutical acceptable salt or solvate thereof.

17. 17. The method of claim 16, wherein the subject has been diagnosed with cancer.

18. 18. The method of claim 16 or claim 17, wherein the subject is on bed rest.

19. The method according to any one of claims 16 to 18, wherein the subject has been diagnosed with age-related sarcopenia.

20. 13. A method for increasing muscle mass in a subject, comprising administering to the subject an effective amount of a compound according to any one of claims 1 to 6, or a pharma- ceutical acceptable salt or solvate thereof.

21. 13. A method of improving muscle strength in a subject, comprising administering to the subject an effective amount of a compound according to any one of claims 1 to 6, or a pharma- ceutically acceptable salt or solvate thereof.

22. 13. A method of improving muscle function in a subject, comprising administering to the subject an effective amount of a compound according to any one of claims 1 to 6, or a pharma- ceutically acceptable salt or solvate thereof.

23. 13. A method for reducing the number of degenerated muscle fibers in a subject, comprising administering to the subject an effective amount of a compound according to any one of claims 1 to 6, or a pharma- ceutical acceptable salt or solvate thereof.

24. 13. A method for increasing the number of regenerated muscle fibers in a subject, comprising administering to the subject an effective amount of a compound according to any one of claims 1 to 6, or a pharma- ceutical acceptable salt or solvate thereof.

25. 10. A method for increasing expression of at least one gene selected from the group consisting of myosin light chain 2, myosin XVIIIb, myomesin 3, lipoprotein lipase, patatin-like phospholipase domain-containing 2, and sarcomeric mitochondrial creatine kinase in a subject, comprising administering to the subject an effective amount of a compound according to any one of claims 1 to 6, or a pharma-ceutically acceptable salt or solvate thereof.

26. The method according to any one of claims 8 to 25, wherein the subject has a mutation in the calpain 3 gene.

27. The method of any one of claims 8 to 26, wherein the subject has been determined to have a deficiency in CaMKII.

28. The method of any one of claims 8 to 27, further comprising determining the expression or activity level of CaMKII.

29. The method of any one of claims 8 to 28, wherein the compound is administered orally, parenterally, subcutaneously, intraperitoneally, or intramuscularly.

30. The method of any one of claims 8 to 29, wherein the compound is administered topically.

31. 31. The method of claim 30, wherein the compound is administered to muscle tissue.

32. The method according to any one of claims 8 to 31, wherein the subject is a human.

Images